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ABSTRACT 
J. JUSTIN MILNER: The Immunological Consequences of Obesity on Primary and Secondary 
Immune Defenses to the 2009 Pandemic H1N1 Influenza Virus. 
(Under the direction of Melinda A. Beck) 
 
Obese individuals are more susceptible to hospitalization and death from infection with 
the 2009 pandemic H1N1 influenza virus (pH1N1). Greater pH1N1 severity in the obese is a 
global public health concern given the persistent threat of influenza outbreaks and the current 
obesity epidemic. In this dissertation, the consequences of obesity on pH1N1 immunity were 
investigated in mice to uncover mechanisms by which obesity enhances pH1N1 illness. During a 
primary pH1N1 infection, 80% of obese mice died compared with 40% of lean, low fat diet fed 
mice and no mortality in lean, chow fed mice. Further, a genetic model of obesity was generated 
in which leptin signaling was conditionally disrupted in hypothalamic neurons to confirm that 
obesity, independent of diet, enhances pH1N1 mortality. Both diet- and genetic-induced obese 
mice exhibited greater lung damage during infection, likely due to fewer lung regulatory T cells 
and impaired regulatory T cell function. We extended our analysis to include a secondary 
heterologous pH1N1 infection model. Obese mice had fewer cross-reactive, non-neutralizing 
pH1N1 antibodies, overactive CD8
+
 effector memory T cell responses and greater lung damage 
in this model.   
During the primary pH1N1 infection, obese mice had greater serum and bronchoalveolar 
lavage leptin concentrations compared with lean mice. Given that leptin regulates T cell 
function, we then determined if conditional disruption of leptin signaling in T cells ameliorates 
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obesity-induced pH1N1 mortality. However, obese mice lacking leptin signaling in T cells were 
not protected from pH1N1 mortality compared with control, obese mice. The pathophysiological 
complications of obesity are diverse and complex. Therefore, we also extended our analysis to 
include 
1
H NMR-based metabolic profiling of urine, feces, serum, lungs, bronchoalveolar lavage 
fluid, mesenteric white adipose tissue, and livers to obtain a more comprehensive examination of 
infection responses in obese mice. We uncovered a number of metabolites and metabolic 
signatures uniquely altered in obese mice that, ultimately, may facilitate early prediction of 
influenza infection outcomes and help to identify mechanisms for impaired. In summary, novel 
immunologic and metabolic techniques were integrated in this dissertation to establish that 
obesity enhances greater lung damage during primary and secondary pH1N1 infections in mice.   
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CHAPTER I: OVERVIEW AND SPECIFIC AIMS 
 
Overview 
Obesity, defined as a body mass index (BMI) ≥30kg/m2, is caused by a prolonged 
positive energy balance (1-3). Excess adiposity increases the risk for a variety of viral and 
bacterial infections (2), and obese individuals were reported to be at greater risk for 
hospitalization and death from infection with the 2009 H1N1 pandemic strain (pH1N1) (4-7). 
Obesity is a global epidemic (8), and influenza epidemics and pandemics are persistent threats 
worldwide (9,10). Therefore, enhancing understanding of the negative impact of obesity on 
pH1N1 immunity is a critical global public health issue. 
The mechanisms by which obesity drives greater influenza infection severity in humans 
are unclear. Although we have demonstrated that obese individuals have impaired cellular and 
humoral immune responses to influenza vaccination (11,12), there is little known regarding how 
obesity impacts dynamic immune responses in the lung during infection in humans. Therefore, 
mouse models of obesity and influenza infection are critical for elucidating potential mechanisms 
with the future prospect of identifying therapeutics, improving disease management and 
influencing vaccination approaches with the ultimate goal of limiting influenza morbidity and 
mortality in this at risk population. 
Despite widespread transmittance, pH1N1 infection illness was surprisingly mild (13). 
The limited severity to the 2009 pandemic H1N1 virus was primarily mediated by pre-existing 
cross-reactive immunity conferred from exposure to previously circulating seasonal influenza 
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strains or vaccination (14). However, because obese individuals were at greater risk for 
pandemic H1N1 severity, we hypothesized that obesity impairs cross-reactive immune defenses 
to pandemic H1N1. We therefore explored this using a mouse model of obesity and heterologous 
immunity (Aim 1).   
Obesity is associated with a chronic inflammatory state (1,2), and the majority of the 
pathophysiological complications of obesity are linked to excess inflammatory immune 
responses both locally and systemically (2). From our analysis of obesity on heterologous 
immunity, we found that obese mice exhibit greater lung damage during a secondary pH1N1 
infection (14). We further extended our analysis to demonstrate that obesity impairs primary 
infection defenses to pandemic H1N1, resulting in greater lung damage and death (Aim 2). 
Obesity is a multifactorial disease resulting in physiological adaptations, metabolic 
perturbations, hormonal changes, alterations in levels of circulating nutrients, greater oxidative 
stress, and changes in the gut microbiome (2). Given the complexity of this disease, it is difficult 
to identify one specific molecular mechanism explaining greater pH1N1 severity in the obese. 
Therefore, we utilized metabolic profiling to obtain a more comprehensive, global perspective of 
the impact of obesity on pH1N1 immunity (Aim 3). Metabolic profiling uncovered a number of 
distinct changes in metabolic pathways and metabolites in influenza-infected obese mice. This 
dissertation facilitates the establishment of metabolomics as a useful tool in characterizing 
influenza pathogenesis, and perhaps as a useful tool for prediction of influenza infection status 
and severity. 
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Specific Aims 
 
Specific Aim 1: Determine if obesity impairs heterologous immunity to infection with the 2009 
pandemic H1N1 virus. 
Hypothesis:  Obese mice will exhibit greater mortality, fewer cross-reactive memory T cells and 
greater lung damage during a secondary 2009 pandemic H1N1 infection. 
 
Specific Aim 2: Determine if obesity impairs primary infection responses to the 2009 pandemic 
H1N1 virus, resulting in greater mortality and lung damage. 
Hypothesis: Obese mice will exhibit greater mortality and lung damage during a primary 
infection with the 2009 pandemic H1N1 influenza virus. 
 
Specific Aim 3: Determine if metabolic profiling of biofluids and tissues can distinguish 
influenza infection status in lean and obese mice and identify novel potential mechanisms for 
greater influenza infection severity. 
Hypothesis: Metabolic profiling will uncover distinct perturbations in metabolic pathways and 
metabolites that allow for identification of new explanatory mechanisms for greater influenza 
severity in obese mice. 
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CHAPTER II: BACKGROUND AND SIGNIFICANCE 
 
Introduction 
In 2009, a novel influenza virus emerged causing the first pandemic of the 21
st
 century 
(15). The 2009 pandemic H1N1 virus (pH1N1) caused widespread infections, and in the US 
alone, approximations of the number infected reach 89 million individuals (16). Although a 
variety of previously established risk factors increased susceptibility for severe pH1N1 
outcomes, for the first time, the obese were reported to be at greater risk for hospitalization and 
death from influenza infection (6). Further, a recent meta-analysis demonstrated that obese 
individuals are at greater risk for severe seasonal influenza infections as well (17). Given that 
more than 500 million individuals are obese (3) and influenza outbreaks are a persistent threat, 
identifying mechanisms for greater influenza severity in the obese is a global public health 
concern. 
 
The obesity epidemic 
Globally, more than 1 in 10 individuals are considered to be obese (BMI≥30kg/m2) (3). 
An array of cultural, ecological, psychosocial and biochemical factors influence weight gain and 
obesity status (1,3). However, ultimately, obesity is caused by a prolonged positive energy 
balance. Excess energy consumption or insufficient energy expenditure results in triacylglycerol 
(TAG) deposition in adipose tissues, and overtime this causes obesity (18). The complications 
and risk factors associated with excess adiposity are diverse and complex and include type II 
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diabetes, cardiovascular disease, cancer, chronic obstructive pulmonary disease (COPD), strokes 
and infections (3,18). An abundance of research focuses on the negative health consequences of 
obesity, and interestingly, excessive inflammation and hyperactive immune responses are linked 
to nearly every comorbidity associated with obesity (2). Further, despite excessive inflammatory 
responses in the obese, excess adiposity predisposes individuals to a variety of infections (2).     
 
Evidence for greater infection susceptibility in obese individuals 
Obese patients have increased intensive care unit (ICU) length of stay (19) and are more 
likely to die (20-22) in the hospital. It has been reported that obesity increases infection 
susceptibility in clinical settings (23), and further, obesity is a well-established independent risk 
factor for postoperative infections (24-34).  In a recent secondary analysis of a large prospective 
observational study including critically ill and injured patients remaining in the ICU for 48 hours 
or more, obesity was reported to be an independent risk factor for catheter and blood stream 
infections (35). In critically injured blunt trauma patients, morbid obesity (BMI≥40) was 
associated with increased risk of pneumonia and urinary tract infection but not with increased 
mortality (27).  
The impact of obesity on clinical outcomes in hospitalized patients is clearly 
multifactorial and complex. For example, underlying disease in the obese may inhibit proper 
mobility in the hospital, which can increase risk for skin breakdown (36). Due to inadequate 
equipment or improperly trained staff, obese individuals may have prolonged visits at the 
hospital, thus increasing risk for acquiring nosocomial infections (23,36). Another consideration 
is that pharmacokinetics of antibiotics may differ in the obese, potentially affecting susceptibility 
to post-operative infections (37). Therefore, it is difficult to determine the direct impact of 
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impaired immunity on severity of nosocomial infections in obese patients, but accumulating 
evidence suggests a significant role. 
Increased BMI is associated with greater risk for several other bacterial infections 
including periodontal infections (38), Staphylococcus aureus nasal carriage (39) and gastric 
infection by Helicobacter pylori (40). Also, a recent study reported that obesity was significantly 
associated with HSV1 infection, which was determined by seropositivity (41). Despite increased 
risk for several types of microbial infections, there is little known about how obesity may alter 
the pharmacokinetics of antimicrobial drugs (reviewed in (37)). Studies assessing dosing of the 
antibacterial drug, vancomycin, suggest that obese patients may require different dosages (42) 
and different dosing intervals (43) compared with non-obese individuals.  An additional study of 
the antimicrobial drug, linezolid, reported diminished serum concentrations in the obese 
compared with healthy-weight volunteers receiving the same dose (44). As pointed out 
previously, there is greater risk of skin breakdown in obese individuals in clinical settings due to 
restricted mobility, improperly sized rooms/equipment and the special challenges of caring for 
patients undergoing or post bariatric surgery (23,36). Additionally, excess adiposity may reduce 
tissue perfusion and affect wound healing (36). Taken together, it is clear that obesity 
predisposes individuals to nosocomial infections, and that careful consideration of infection 
prevention and treatment is required.  
In contrast to the recent surge of publications highlighting a connection between 
influenza severity and obesity (discussed below), there is very little known about obesity and 
other respiratory tract infections (45). A recent study by Akiyama et al. suggests that obesity may 
impact the response to respiratory syncytial virus (RSV) infection in children (46). A study from 
Poland reported that BMI was significantly related to susceptibility to respiratory infections in 
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children (47). In critically ill trauma patients, obesity or morbid obesity was associated with 
respiratory infections (20,29,35). Conversely, a few studies have also reported obese individuals 
are not at greater risk for respiratory infections (19,48). Therefore, our understanding of the 
effect of obesity on risk for pulmonary infection remains unclear. However, it is important to 
consider that obesity can complicate lung mechanics, such as restricting lung volume (49), which 
could potentially increase risk for pneumonia or other infections. Although the mechanisms 
contributing to increased susceptibility may include impaired immunity, there may be non-
immune factors to consider.  
 
Obesity and host defense in rodents 
A limited number of studies have demonstrated the negative impact of excess adiposity 
on host defense in rodent models. The implications of these studies, in terms of obesity-related 
immunity impairments, are often complicated by the use of genetic models of obesity. The most 
commonly used genetically altered rodents for this purpose are the ob/ob and db/db mice and the 
rat fa/fa counterpart. These rodent models lacking leptin or the leptin receptor can be useful for 
the study of obesity-related comorbidities, as they display metabolic abnormalities characteristic 
of obesity such as hyperglycemia, dyslipidemia, glucocorticoid excess and hyperinsulinemia 
(50,51) (all of which could potentially alter immune cell homeostasis and function). However, 
given the vast amount of research highlighting the importance of leptin in immunity (52), a 
global deficiency in leptin signaling makes it difficult to tease apart the mechanisms contributing 
to impaired immunity and greater susceptibility to infections in these genetic models of obesity.  
Nonetheless, these models still provide insight into how excess adiposity may directly or 
indirectly alter immune cell function and host defense against infectious agents.   
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In general, a deficiency of leptin (ob/ob) or the leptin receptor (db/db) in mice increases 
susceptibility to bacterial infections and pneumonia (45). Using ob/ob mice, Mancuso et al. 
demonstrated that a complete deficiency of leptin resulted in impaired pulmonary clearance upon 
Klebsiella challenge, likely due to defective alveolar macrophage and neutrophil phagocytosis 
(53). Similarly, an investigation by Hsu et al. reported that ob/ob mice exhibited enhanced 
lethality and delayed clearance of Streptococcus pneumoniae following a pulmonary challenge 
(54). Interestingly, intraperitoneal injections of leptin prior to Streptococcus infection improved 
survival after the bacterial challenge, but not to the level of wild-type mice. This discrepancy in 
survival percentages may, in fact, be caused by the increased adiposity of the ob/ob mice. Other 
studies have reported that ob/ob mice exhibit greater pulmonary Mycobactrium tuberculosis load 
(55) and delayed clearance of the Mycobacterium abcessus (56) upon challenge.  
In addition to these pulmonary infection models, mice lacking the leptin receptor were 
shown to be more susceptible to hind paw staphylococcal infection and exhibited a greater 
inflammatory response compared with wild-type mice (57). Furthermore, db/db and ob/ob mice 
displayed impaired resistance to hepatic Listeria monocytogenes infection (58). Obese Zucker 
rats show decreased ability to clear yeast infection upon challenge with Candida albicans (59). 
It is clear that evidence highlighting the importance of leptin for host defense is rapidly 
accumulating. However, these studies do not offer insight into the mechanisms by which excess 
body fat (and associated metabolic abnormalities) may actually hinder host defense. Adding 
exogenous leptin to ob/ob mice is helpful in understanding the impact of other metabolic 
abnormalities on immune dysfunction, but exogenous administration of leptin in mice still differs 
from studying animals with intact leptin production and signaling. Some key considerations 
include indirect effects of leptin on immune responses and the fact that leptin has been shown to 
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have autocrine signaling capabilities on select immune cells. Although infection models in ob/ob 
or db/db mice provide important information on the role of leptin in host defense and immunity, 
these mice do not properly model non-genetically induced obesity, which constitutes the vast 
majority of human obesity.  
  Diet-induced obesity (DIO) in rodents more closely mimics human obesity compared 
with genetic models of obesity. DIO mice develop the prototypical comorbidities associated with 
obesity including hyperleptinemia, insulin resistance, white adipose tissue inflammation, low-
grade systemic inflammation and greater liver TAG deposition to name a few. These DIO 
models are most frequently used to study metabolic perturbations associated with obesity, 
however, few studies have utilized these models to determine the impact of obesity on host 
defense. Compared with lean control mice, DIO mice have greater morbidity and mortality 
during either a primary or secondary influenza infection (60,61) (discussed further below). An 
investigation by Shamshiev et al. reported apoE
-/-
 mice fed a high fat/cholesterol diet displayed 
impaired resistance to Leishmania major infection due to impaired dendritic cell function and T-
helper type 1 (TH1) cell immunity (62). Impaired T-cell activity was also reported in DIO mice 
transgenic for a T-cell receptor specific to a peptide derived from ovalbumuin (63). Utilization of 
DIO models in mice will help to better inform about the potential factors responsible for 
increasing infection susceptibility in obese humans.  
 
Dietary considerations in mouse models of obesity 
One complication associated with DIO models is elucidating whether the observed 
outcome of infection can be attributed to the complications of excess adipose tissue, the 
influence of the high fat diet or both. In this case, utilizing both genetic models of obesity and 
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DIO models in tandem may be beneficial in advancing our understanding of the impact of the 
diet vs. obesity status on immunity (64,65). Another important aspect of DIO studies to consider 
is use of a proper control diet. A purified, nutrient defined, high fat lard-based diet is commonly 
used for DIO models, and it is generally established that the proper control diet for lean mice is 
also a purified, nutrient defined low fat diet differing only in fat and carbohydrate content (66). 
However, chow diets are commonly used for lean control groups, which can introduce a variety 
of confounding variables (67,68). In addition to differences in macro and micronutrient 
composition between chow diets and purified high fat diets, chow diets also contain other 
nutrients such as phytoestrogens (plant derived chemicals with estrogenic activity), fiber and 
other known and unknown plant constituents (66,69). These variables could potentially confound 
results from DIO studies. Further, various batches of chow diets (even from the same company) 
are often produced with varying levels due plant components (in part driven by what plants are 
cheapest at the time) (69). Therefore, there is legitimate concern that experimental 
reproducibility is at risk when chow diets are used. With that said, there is an inherent limitation 
in mouse diet studies for utilizing the proper control diet, because regardless of whether or not 
the ingredients are purified, there will still be differences in fat content and carbohydrate content 
between high fat and low fat diets. Further, the standard 10% kcal fat, low fat diet, is high in 
sucrose, which may cause metabolic perturbations on its own (70). Now available are new low 
fat control diets that replace sucrose with other carbohydrates. Nonetheless, careful consideration 
of diet and experimental design is important in assessing the impact of obesity or diet on 
immunity. 
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Obesity and influenza infection in humans and mice 
A striking number of recent studies have reported obesity to be a predictor for a worse 
outcome of infection with pH1N1 (71). In fact, several countries across the world have reported 
that obese individuals were disproportionately represented among influenza-related 
hospitalizations and deaths. Obesity or morbid obesity increased risk of ICU admission and even 
death among those infected with the pandemic strain (72-75). Those admitted to ICUs had a 
reportedly longer duration of mechanical ventilation, and increased time in ICUs and hospitals 
compared with healthy weight individuals (76). Before the advent of the 2009 pandemic season, 
there were no such reports investigating the relationship between obesity and influenza infection 
in humans. Recently, however, Kwong and colleagues published a study which explored the 
relationship between BMI and seasonal influenza infection using a series of Canada’s cross-
sectional population based health surveys (77). The surveys covered 12 influenza seasons. 
Analysis of the retrospective cohort demonstrated that the obese are at greater risk for respiratory 
hospitalizations during the seasonal flu periods. Lastly, a meta-analysis performed by Mertz et al. 
found that obesity was an independent risk factor for severe outcomes to seasonal influenza 
outbreaks as well (17).  
A number of studies have demonstrated that obesity results in greater morbidity and 
mortality following influenza virus infection in mice (14,68,78-81). Although it is currently 
unclear whether obesity enhances viral replication in the lungs, it is clear that obesity modulates 
several aspects of the immune response (14,78,79). Both innate and adaptive arms of immunity 
are impaired during influenza infection as demonstrated by altered natural killer (NK) cell, 
dendritic cell (DC), T cell, B cell and heterologous memory responses (2). Further, obesity drives 
greater lung pathology and/or inflammation during influenza infection, and obese mice exhibit 
12 
 
impaired lung wound healing during infection (14,67,78). Of interest, it was recently 
demonstrated that monoclonal antibody neutralization of leptin, an adipocyte derived hormone 
that is chronically elevated in an obese state, during infection with pH1N1 improved infection 
outcome in obese mice (82). However, despite a number of publications investigating the 
contribution of obesity on the immune response to influenza infection, there are currently no 
clearly established cellular or molecular mechanisms. 
 
Influenza virus biology  
Influenza is a contagious respiratory disease caused by the influenza virus (83). There are 
three types of influenza viruses, A, B and C (83). Influenza A virus is responsible for the 
majority of infections in humans and typically results in the more severe infection illness 
compared with types B and C (9,83). Influenza B also commonly infects humans but induces 
mild illness, and influenza C can infect humans but is only associated with very minor symptoms 
(9,83). Influenza virus is a zoonotic, negative sense RNA virus of the Orthomyxoviridae family 
(83). Each influenza virion contains an envelope derived from host cells and 8 segmented RNA 
molecules that make up the genome of the virus (83). The encoded viral proteins include 
hemagluttinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2), 
nucleoprotein (NP), polymerase acid (PA), polymerase basic 1 and 2 (PB1/2), non-structural 
protein 1 (NS1), non-structural protein 2 (NS2 or NEP) and some strains also express the pro-
apotoptic protein PB1-F2 (83,84). Each protein serves a distinct and specialized purpose. HA is a 
surface glycoprotein that binds to sialyic acid receptors on epithelial cells in the respiratory tract 
of humans as well as intestines in birds (83,85,86). NA cleaves sialic acid moieties to enhance 
viral spread from infected cells (83). HA and NA are particularly important because they are 
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major determinants of influenza virus infectivity and also form the basis for influenza virus 
subtyping (83). Thus far, 17 different HA molecules and 9 different NA molecules have been 
identified (87).  
Influenza infection is first mediated by HA binding to cellular sialic acid receptors of an 
α2,6 and/or an α2,3 conformation (83,86). HA is then cleaved by cellular proteases which 
triggers receptor mediated endocytosis (86). The low pH of intracellular endosomes triggers a 
conformational change in the HA trimer that allows fusion of the endosomal membrane and the 
viral envelope (86). Simultaneously, the M2 protein functions as an ion channel and pumps H
+
 
into the virion, resulting in the disassembling of the virion and release of viral contents from the 
endosomal compartment into the cellular cytoplasm (83). Ribonucleoproteins containing the 
viral genome bound by nucleoprotein and the polymerase trimer are imported into the nucleus 
(83). Herein, influenza derived RNA-dependent RNA polymerases began transcribing the 
negative sense RNA into complimentary viral RNA, vRNA (88). The vRNA molecules are 
exported to the cytoplasm where they are translated by host machinery or remain in the nucleus 
for genome replication (88). Newly synthesized viral proteins are trafficked to the host 
membrane via the Golgi apparatus or enter back into the nucleus of the cell. New vRNA 
molecules and translated viral proteins are packaged into progeny virions at the surface of the 
cell (88). Finally, new virions bud from the cell, obtaining an envelope from the host membrane. 
Here, neuraminidase is critical for cleaving HA and sialic acid interactions to allow further 
spread of new progeny virions (83). 
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Antigenic drift, antigenic shift and highly pathogenic influenza viruses 
Influenza virus causes seasonal outbreaks that result in up to 500,000 deaths every year 
(9). Unlike long-lived memory responses to other viruses such as yellow fever, immunity 
conferred by influenza virus infection or vaccination may not be protective to subsequent 
exposure of influenza. This is primarily due to antigenic drift (89). The influenza RNA-
dependent RNA polymerase replicates with low fidelity, meaning that nucleotide “errors” are 
commonly introduced (at a rate of 1 in 1000 nucleotides) (83,89). These point mutations in the 
viral genome can result in antigenic and functional changes in viral proteins, affecting host 
immunity and/or viral infectivity. Antigenic drift is also the reason that influenza vaccination is 
recommended yearly (discussed further below) (89).  
In addition to point mutations in the viral genome, influenza can also undergo major 
genomic changes through “swapping” of the segmented RNA molecules. This is called antigenic 
shift, and is the basis for the genesis of influenza pandemics (89). This reassortmant of genetic 
material occurs when at least two different influenza viruses infect the same cell, resulting in 
progeny virions with a novel combination of influenza RNA segments (and thus a novel 
combination of proteins). Generation of novel influenza strains primarily occurs from 
reassortment in swine (90). This is because epithelial cells in swine express sialic acid receptors 
of both the α2,6 and the α2,3 conformations (89,90). Influenza strains primarily circulating in 
humans preferentially bind to the α2,6 conformation (in the upper respiratory tract), whereas 
avain strains typically bind receptors of the α2,3 structure (systemically) (83). This is one critical 
barrier that prevents transmittance of highly pathogenic avian strains to humans. Novel influenza 
strains created from genetic shifting are a pertinent public health threat because often the general 
population lacks any pre-existing immunity to such viruses. There have been 5 influenza 
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pandemics, and the first pandemic of the 21
st
 century occurred from the emergence of the triple 
reassortant 2009 pandemic H1N1 influenza virus (discussed further below) (90).  
In birds, influenza virus is systemic (91). This is primarily due the presence of a 
multibasic cleavage site on the HA trimer in avian strains (91,92). In human strains, cleavage of 
HA is restricted to cellular proteases primarily found in the respiratory tract (such as trypsin), 
thus limiting infection to that compartment (92). However, in avian strains, this multibasic 
cleavage enhances viral tropism to epithelial cells of the digestive tract and possibly other organs 
as well (91,92). Therefore, reassortment of a contagious human virus with an HA from an avian 
strain could result in a severely lethal influenza virus in humans. In fact, in 2003 a novel avian 
strain, H5N1, emerged in China (10). Despite a 60% mortality rate, the highly pathogenic strain 
has shown limited human to human transmission, preventing a pandemic outbreak for the time 
being (10). However, as mentioned, the influenza genome is highly susceptible to mutations, and 
it has been demonstrated that only 5 mutations in HA of H5N1 are required for human to human 
transmission (10). Because influenza viruses do not readily transmit between birds and humans, 
it is thought that humans become infected with avian strains due to close contact with poultry 
(93). Recently, another novel avian strain, H7N9, emerged in China in March 2013 (94). H7N9 
was not previously detected in humans until this point in time (94). Similarly, this virus does not 
appear to transmit well among humans, but those infected become severely ill (94). Persistent 
surveillance of these highly pathogenic influenza strains is important part of preventing future 
pandemics. Further, it is clear that obese individuals are more susceptible to influenza severity 
caused by seasonal strains and the 2009 pH1N1 strain, and thus obese individuals may be even 
more susceptible to severe infection outcomes from these avian strains (2).       
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The 2009 pandemic H1N1 influenza virus 
The 2009 pandemic H1N1 influenza A virus (pH1N1) is unique in several aspects. 
Despite causing greater disease severity in animal models compared to seasonal H1N1 strains 
(95-98), the pH1N1 virus caused relatively mild illness in the majority of humans without 
predisposing risk factors (13,99). Further, in contrast to seasonal influenza epidemics, children 
and nonelderly adults were more susceptible to pH1N1 infection compared with elderly 
individuals (15,100). It has been estimated that approximately 90% of pH1N1 deaths occurred in 
the nonelderly population (101). Further epidemiological evidence suggests the lower 
susceptibly in elderly individuals is likely due to the presence of anti-hemagluttinin antibodies 
generated from previous exposure to pre-1950 influenza strains that cross-react with the novel 
pH1N1 virus (100,102-104). However, the majority of the population is naïve to these past 
circulating influenza strains. Further, recently circulating (pre-2009) seasonal strains and 
influenza vaccines did not elicit a robust cross-reactive neutralizing antibody response. 
Therefore, most individuals lacked pre-existing neutralizing antibody protection against pH1N1 
infection (102,104-107). 
 
Innate defenses to influenza virus infection in the lung 
Influenza virus is primarily spread through mucous or air-born aerosols. The initial 
responders to influenza virus infection are also the primary target of the virus, respiratory 
epithelial cells (108). Influenza virus pathogen associated molecular patterns (PAMP) trigger 
induction of innate antiviral responses in epithelial cells. The primary pattern recognition 
receptors (PRR) for invading influenza virions include endosomal toll like receptors 3/7 
(TLR3/7) and cytoplasmic retinoic acid inducible gene I (RIG-I), all of which recognize 
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influenza vRNA (108,109). PRR recognition of these PAMPs triggers activation of several 
inflammatory pathways that ultimately induce the production of type I interferons (IFN), 
chemokine production and inflammatory cytokine production (108,110,111). IFNα and IFNβ are 
secreted within a few hours after an infected cell recognizes the invading virus, and these type I 
interferon’s are critical for communicating the presence of a viral infection to neighboring 
epithelial cells, making them poised to fight the ensuing infection (110,111). Chemokines 
produced from infected epithelial cells result in a robust infiltration of early responding innate 
immune cells (108,110,111). Simultaneously, innate immune cells, such as DCs and alveolar 
macrophages already present in the lung at the time of infection help to propagate this 
inflammatory response by producing cytokines and chemokines as well (108,111). 
Approximately the first 5 days of the immune response to influenza virus infection is 
predominantly comprised of innate defenses (112). Macrophages, NK cells, DCs and neutrophils 
migrate into the lung in attempt to combat the infection (111). Macrophages and neutrophils are 
critical for phagocytizing virus particles, infected cells and inflammatory debris (108,111). NK 
cells target infected cells for lysis, distinguishing infected from uninfected cells by conserved 
cellular patterns. Lastly, DCs engulf viral particles, and present influenza virus antigens on major 
histocompatibility complexes I and II (MHCI and MHCII) to stimulate induction of the adaptive 
immune response (108,111).   
 
Adaptive immunity to influenza virus 
Activated dendritic cells presenting influenza virus antigen migrate to the draining lymph 
node of the lung to trigger activation of influenza-specific T cells and B cells (113,114). CD4
+
 T 
cells recognize cognate antigen on MHCII molecules and CD8
+
 T cells bind influenza epitopes 
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on MHCI molecules (114,115). T cells are constantly surveying the blood and lymph, and those 
specific for influenza virus will bind to MHC molecules and become activated and undergo 
clonal expansion in draining lymph nodes (114,116). Influenza-specific T cells accumulate in the 
draining lymph node, and can be detected in the lung as early as 5-6 days post-infection (dpi) 
(113,117). However, the number of infiltrating T cells peaks between 8 and 10 dpi (117). 
Effector CD8
+
 T cells are critical for controlling the infection by targeting infected cells by lysis 
(113). Further TH1 cells, the primary CD4
+
 T cell lineage generated during influenza, can also 
target infected cells for lysis (116). Additionally, CD4
+
 T cells are critical for proper induction of 
antibody defenses to influenza virus (113). 
 
Memory responses to influenza virus infection 
Following robust expansion of influenza-specific T cells, a majority of the cells undergo 
apoptosis following viral clearance (118). However, a small proportion of these cells become 
long-lived memory T cells (118). Memory T cell responses are critical for protection against 
subsequent influenza virus infections. Although the exact mechanisms regulating the generation 
and maintenance of memory T cells are unclear, a number of modulatory factors have been 
defined, including inflammatory responses during the primary infection, cellular metabolism, 
and tissue migration (118,119). Memory T cells consist of primarily two different types, central 
memory T cells (Tcm) and effector memory T cells (Tem (118)). Tem are primarily found at the 
site of infection and are early responders to re-infection, serving as an early control of viral 
replication (118). Tcm are primarily found in circulation and mount a more robust and dynamic 
response to ultimately resolve a secondary infection (118). 
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Antibodies are the earliest line of defense protecting from influenza virus infection. B 
cells containing a B cell receptor specific to influenza antigens primarily recognize cognate 
antigen in draining lymph nodes through DC presentation (120). B cells can become activated, 
independent of T cell help, and these are primarily early sources of influenza-specific antibodies 
referred to as short-lived plasma cells (120,121). Additionally, the majority of activated B cells 
migrate to the germinal center of the draining lymph node where they interact with follicular 
helper T cells (Tfh) through MHCII and costimulatory molecules (120,121). This interaction is 
critical to the formation of effective antibody defenses because it triggers the generation of long-
lived plasma cells and memory B cells (120,121). Long-lived plasma cells home to bone 
marrow, where they continue to secrete influenza antibodies for extended periods of time (likely 
throughout a lifetime) (120,121). Influenza-specific memory B cells can be found in circulation 
and in nearly every tissue and induce an accelerated and robust plasma cell response following 
re-infection (120). Influenza memory responses are the basis for effective influenza vaccination.   
 
Influenza virus vaccination 
Vaccination to influenza virus is widely accepted as the best measure to protect against 
influenza infection and to limit influenza infection severity (122,123). An abundance of research 
focuses on novel approaches to vaccinate individuals to the ever-changing influenza strains 
(123). The primary methods of vaccination include intramuscular immunization with the 
trivalent inactivated influenza vaccine (TIV) or intra-nasal administration of a live-attenuated 
influenza vaccine (LAIV) (122,123). Both vaccines include the three influenza strains, two type 
A strains (H1N1 and H3N2) and one B strain (122,123). These strains are chosen based on 
influenza surveillance data indicating the most actively circulating strains. During the 2013-2014 
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influenza season, a quadrivalent vaccine was available, including two influenza A strains and 
two B strains (123). At this point, it is unclear which type of vaccine (TIV vs. LAIV) offers 
better protection, but both vaccines have been shown to protect against influenza infection in 
humans (122,124). The purpose of influenza vaccination is to induce long-lived, protective 
antibody and memory T cell responses that serve to protect upon exposure to influenza virus 
(124). Vaccine antigen is taken up by dendritic cells in draining lymph nodes of the arm (TIV) 
and the respiratory tract (LAIV) where it can be presented to T cells and B cells as described 
above.  
Influenza vaccines have been shown to reduce the number of individuals infected with 
influenza and to reduce illness severity in the infected (122,124). However, there is some 
evidence suggesting that obese individuals may not respond to vaccination to the same extent as 
healthy weight individuals (2). Obesity was associated with a poor antibody response to hepatitis 
B vaccination (125,126). Additionally, overweight children displayed significantly lower anti-
tetanus immunoglobulin G (IgG) antibodies in response to vaccination compared with healthy 
weight children (127). Interestingly, it has been reported that using a larger vaccine needle length 
resulted in significantly higher antibody titers to hepatitis B surface antigen in obese adolescents 
(128). Studies from our lab have demonstrated that obese individuals have impaired cellular and 
humoral responses to TIV immunization. Although obese individuals are able to mount a 
comparable antibody response one month after vaccination compared with healthy weight adults, 
one year after vaccination obese individuals display a reduced ability to maintain influenza 
antibody levels (12). Further, both influenza-specific CD4
+
 and CD8
+
 memory T cell responses 
following vaccination are blunted in obese adults (11,12). Taken together, obesity impairs 
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influenza vaccination responses, potentially predisposing this at-risk population to greater 
infection severity.  
 
Heterologous immunity 
Neutralizing antibodies are critical for the control and even prevention of influenza 
infection (120). In their absence, influenza-specific memory T cells are critical regulators of viral 
spread and influenza severity (113,129). A number of studies in animals and humans have 
demonstrated that prior exposure to seasonal influenza viruses or vaccination can induce cross-
reactive memory T cells that have the capacity to limit pH1N1 disease severity (107,130-135). In 
mice, seasonal influenza virus infection or vaccination elicits a memory T-cell response that can 
prevent morbidity and mortality to a lethal pH1N1 challenge (133,136-139). Additionally, 
seasonal influenza A-specific memory T cells from humans, naïve to the pH1N1 virus, are 
capable of recognizing pH1N1 and can directly lyse pH1N1-infected target cells (131). 
Therefore, the ability of cross-protective memory T cells to control pH1N1 infection is a critical 
mediator for the relatively benign symptoms experienced by a majority of those infected 
(131,140).  
Although the majority of research on heterologous immunity to influenza infection 
focuses on T cell responses, cross-reactive antibody protection to pH1N1 cannot be ignored. 
Non-neutralizing antibodies recognizing conserved epitopes, such as NP antibodies, have been 
shown to contribute heterologous protection to influenza infection, reducing viral titers and 
infection severity in mice (141,142). Although it is currently unclear how non-neutralizing 
antibodies mediate protection to influenza virus, it is likely achieved through induction of 
antibody complexes in the respiratory tract. An additional mechanism by which antibodies may 
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confer protection during a heterologous pH1N1 infection is through accelerated production 
(compared with antibody production in naïve mice) of homologous pH1N1 antibodies. This is 
likely triggered by cross-reactive memory CD4
+
 cells that facilitate accelerated B cell activation 
and antibody production (137,142). 
 
Mechanisms by which obesity may impair immune cell function 
It is well known that obesity is associated with a state of chronic, low-grade inflammation 
both in white adipose tissue (WAT) and systemically (143-146). Additionally, obesity is 
characterized by altered levels of circulating hormones and nutrients such as glucose and lipids. 
Circulating and tissue resident immune cells are thus exposed to an energy rich environment in 
the context of altered concentrations of metabolic hormones and inflammatory cytokines. 
Understanding how this pro-inflammatory, excess energy milieu impacts immune cell function is 
key in understanding greater susceptibility to pH1N1.  
Hyperinsulinemia and insulin resistance are common features of obesity; however, there 
is little known regarding the immunomodulatory effects of excess insulin or impaired insulin 
signaling in the context of obesity. Monocytes have been shown to express insulin receptors and 
are insulin sensitive immune cells (147-150). Interestingly, resting T cells are insulin insensitive 
in that the insulin receptor is absent from the plasma membrane. However, upon activation, 
effector T cells upregulate de novo emergence of insulin receptors (151,152). Insulin signaling 
induces glucose uptake, amino acid transport, lipid metabolism and can modulate T cell 
activation and function (151,153).  Furthermore, insulin promotes an anti-inflammatory TH2 cell 
phenotype (152), and  MacIver et al. speculate that insulin resistance in obesity may actually 
enhance TH1 cell development (154). Macrophage function and ER stress responses are also 
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modulated by insulin receptor signaling (1,2). Thus, it is clear that insulin can have potent effects 
on immune cell metabolism and function, but the effects of hyperinsulinemia or insulin 
resistance on immunity remain relatively unknown. 
 
Leptin and immunity in the obese  
The primary adipose derived immunomodulatory adipokines include leptin, adiponectin, 
and the pro-inflammatory cytokines: tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and 
IL-1β (144,145,155). Adiponectin, levels of which are decreased during obesity, has been shown 
to alter NK cell cytotoxicity and cytokine production by human myeloid cells (156,157). 
Conversely, there is excess production of TNF-α, IL-6 and IL-1β in WAT of the obese (145). 
These cytokines can be secreted into circulation and potentially have distal effects; however, 
exactly how chronic production of these cytokines impacts cellular immunity remains to be 
elucidated. It is possible that chronic exposure to pro-inflammatory cytokines may desensitize 
immune cells to inflammatory responses during an actual infection (158).   
The pleiotropic effects of leptin on immune cell activity are highly diverse (52), and the 
function of nearly every innate immune cell has been shown to be modulated by leptin signaling 
(159-163). In monocytes, leptin upregulates pro-inflammatory cytokine production of IL-6, IL-
12 and TNF-α as well as phagocytic activity (53,164,165). In polymorphonuclear neutrophils of 
healthy individuals, leptin signaling induced chemotaxis, reactive oxygen species (ROS) 
generation and influences oxidative capacity (163,166,167). NK cells are highly influenced by 
leptin signaling, including aspects of differentiation, proliferation, activation and activity 
(161,168). Given the importance of leptin to innate immune cell function, it follows that nearly 
all innate immune cells are impaired in mice lacking intact leptin signaling (2). 
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Leptin also plays a critical role in regulating adaptive immunity (159,162). Leptin is an 
important source of pro-survival signals to double-positive and single-positive thymocytes 
during the maturation of T cells (169). Leptin has been shown to play a key role in 
lymphopoieses and myelopoieses given that ob/ob mice have only 60% as many nucleated cells 
in bone marrow as compared with wild-type controls (170). In the presence of a polyclonal 
stimulator, leptin can increase T cell proliferation and can modulate expression of activation 
markers on both CD4
+
 and CD8
+
 T cells (171).   
Although several papers have discussed how leptin may be required for, or may enhance 
immune cell function, few have taken into consideration how hyperleptinemia in obese 
individuals may modulate immune cell function (172). Additionally, elevated levels of leptin 
have been shown to induce a state of central leptin resistance. Indeed, studies have demonstrated 
that T cells (162) and NK cells (173) can become resistant to leptin in rodent models of obesity. 
Leptin signals through a variety of pathways, the most studied being the Jak/Stat signaling 
pathway. Leptin receptor activation results in the translocation of the transcription factor, STAT-
3, into the nucleus and subsequent transcription of leptin induced genes, including suppressor of 
cytokine signaling-3 (SOCS-3). SOCS-3 functions as a negative feedback mediator of Jak/Stat 
signaling, and thus may play an important role in impairing leptin signaling and contributing to 
central and peripheral leptin resistance (174).  Leptin resistance, induced by hyperleptinemia, 
would obviously not occur in ob/ob mice, which is another reason these mice are not the best 
model for studying obesity-related immune dysfunction. Although it is widely accepted that 
leptin resistance occurs centrally in the hypothalamus (174-176), peripheral leptin resistance 
requires further investigation. Additionally, it is likely that differing immune cells respond 
differently to hyperleptinemia.  
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Additional considerations of the consequences of obesity on immunity 
In addition to perturbations in circulating levels of nutrients and hormones, there are a 
variety of other pathophysiological complications of obesity that may contribute to excessive 
antiviral responses and lung damage during influenza infection. Obesity induces a state of 
oxidative stress (177), which has been shown to increase influenza severity in mice (178). 
Further, a hallmark of obesity is a state of chronic, low-grade inflammation (2), which may 
compromise the immune response to influenza infection or vaccination. Finally, obesity is 
associated with distinct changes in the intestinal microbiome (179), which may potentially 
impact antiviral responses given that manipulation of the intestinal microbiota in mice can 
influence influenza infection outcome (180). 
 
Metabolic profiling and infectious disease 
Given the large number of mechanisms that may contribute to alterations in immune 
processes during influenza infection in the obese, narrowing focus to one particular mechanism, 
cell type or molecular pathway may not be the best approach to addressing this problem. 
Perhaps, given the complexity of obesity, a systems biology approach may be useful in 
identifying the complicated interactions of underlying mechanisms driving greater infection 
severity. Obesity is inherently a metabolic disease, and therefore, of the many integrative 
systems approaches, we believe metabolic profiling could be a useful tool in identifying 
perturbations in lung-specific and systemic metabolites altered by obesity during influenza 
infection. 
Metabolomics is a technique that allows for biochemical profiling of all small molecules 
that constitute the metabolome (181). Metabolic profiling is useful because it provides a more 
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global view of complex processes occurring during disease and can actually serve as a snapshot 
of cellular processes that have just occurred on a cellular, tissue or systemic level (181). Standard 
processing of samples for metabolomics typically involves identifying and quantitating 
metabolite levels using 
1
H Nuclear Magnetic Resonance (
1
H NMR) or Mass Spectometry (MS). 
1H NMR doesn’t not require separation of compounds whereas MS requires prior separation of 
analytes (commonly through gas chromatography or liquid chromatography separation) (181).  
Uncovering metabolic biomarkers and patterns of altered metabolites would provide a more 
global view of the impact of obesity on dynamic infection responses and simultaneously may 
address the complicated interactions of the molecular underpinnings driving obesity-induced 
influenza mortality. Metabolomics has been used to characterize the metabolic consequences of 
several types of infections in mice including parasitic (182,183), viral (184,185) and bacterial 
infections (186). Further, metabolomic analyses of models of lung inflammation have also 
identified unique metabolites associated with lung damage or greater inflammation (187-189). In 
all of the referenced models of infectious and inflammatory diseases, metabolomics was able to 
identify novel biomarkers and metabolic signatures discriminating infected and uninfected 
groups. In some cases, metabolomics has been used as a novel technique to improve diagnostic 
measures (184,185), whereas in other instances metabolomics has been used to enhance 
understanding of pathways driving disease severity (186-188). Identification of biomarkers or 
predictive metabolic signatures could be used in clinical settings to enhance influenza diagnosis 
and/or treatment of severely infected obese individuals.  
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CHAPTER III: DIET-INDUCED OBESE MICE EXHIBIT ALTERED 
HETEROLOGOUS IMMUNITY DURING A SECONDARY  
2009 PANDEMIC H1N1 INFECTION
1
  
 
Introduction 
The novel 2009 pandemic H1N1 influenza A virus (pH1N1) is unique in several aspects.  
Despite causing greater disease severity in animal models compared to seasonal H1N1 strains 
(95-98), the pH1N1 virus caused relatively mild, uncomplicated symptoms in humans (13,99). 
Further, in contrast to seasonal influenza epidemics, children and nonelderly adults were 
disproportionately susceptible to pH1N1 infection compared with elderly individuals (15,100), 
with estimates that approximately 90% of pH1N1 deaths occurred in the nonelderly population 
(101). Clinical and epidemiological data suggest the lower susceptibly in individuals over 65 y of 
age is likely due to the presence of cross-reactive anti-hemagglutinin antibodies generated from 
previous exposure to pre-1950 influenza strains (100,102-104). Because a majority of the 
population is naïve to these past circulating influenza strains, and recently circulating (pre-2009) 
seasonal strains and influenza vaccines did not elicit a robust cross-reactive antibody response, 
most individuals lacked neutralizing antibody protection against pH1N1 infection (102,104-107). 
Although antibodies are important for the control and even prevention of influenza 
infection, in their absence, influenza-specific T cells are essential in limiting influenza severity 
                                                          
1This chapter was published in the Journal of Immunology: 
J. Justin Milner, Patricia A. Sheridan, Erik A. Karlsson, Stacey Schultz-Cherry, Qing Shi, 
Melinda A. Beck. J Immunol. 2013 Sep; 191(5): 2474-85. 
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(113,129). Several recent studies in animals and humans have demonstrated that previous 
exposure to seasonal influenza strains or vaccination can induce cross-reactive memory T cells 
that have the capacity to limit pH1N1 disease severity (107,130-135). In mice, seasonal influenza 
viruses and vaccines elicit a memory T-cell response that can prevent morbidity and mortality to 
a lethal pH1N1 challenge (133,136-139). Additionally, seasonal influenza A-specific memory T 
cells from humans (naïve to pH1N1) are capable of recognizing pH1N1 epitopes and can directly 
lyse pH1N1-infected target cells (131). Therefore, the ability of cross-protective memory T cells 
to control pH1N1 infection could explain the relatively benign symptoms experienced by a 
majority of those infected (131,140). However, cross-reactive antibody protection to pH1N1 
cannot be ignored. Non-neutralizing antibodies recognizing conserved epitopes, such as anti-
nucleoprotein (NP) antibodies, have been shown to contribute heterologous protection to 
influenza infection, reducing viral titers and infection severity in mice (141,142). Additionally, a 
primary seasonal infection can lead to an accelerated production of pH1N1 antibodies during a 
heterologous pH1N1 infection, which may facilitate pH1N1 viral clearance (137,142). 
Another novel characteristic of the pH1N1 virus is that obesity, defined as a BMI ≥ 
30kg/m
2
, was considered to be an independent risk factor for increased morbidity and mortality 
following infection (4-7,190). Obesity is a global public health concern, affecting more than one-
in-ten of the world’s adult population (3). It is well-established that obesity impacts several 
aspects of the immune response and increases susceptibility for a variety of pathogens, including 
influenza virus (2). Although recent investigations in mice and humans have begun to elucidate 
potential mechanisms by which obesity impairs anti-viral immunity to influenza infection, the 
specific factors contributing to the increased severity observed in the obese population remain 
unclear (2). We have previously demonstrated that obese mice and humans exhibit impaired 
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memory CD8
+
 T-cell responsiveness to influenza stimulation (12,78). Further, obese mice 
display impaired responsiveness to influenza vaccination (68) , and obese humans are unable to 
maintain long-term influenza antibody levels following vaccination (12). Therefore, given the 
protective nature of cross-reactive antibody and T-cell responses, we hypothesized that obesity 
impaired heterologous immunity induced by previous influenza exposure, resulting in greater 
pH1N1 infection severity.  
In this study, we utilized a model in which lean and obese mice were initially infected 
with a sublethal dose of influenza A/PR/8/34 (H1N1, PR8). After 5 wk (to allow contraction of 
effector T cell responses), mice were challenged with a lethal dose of heterologous pandemic 
A/Cal/04/09 (H1N1, pH1N1). Similar to results shown previously in lean, chow fed mice (133), 
we found that priming with PR8 effectively prevented mortality from pH1N1 infection in both 
lean and obese mice in the absence of cross-reactive neutralizing antibodies. However, obese 
mice exhibited a lower level of cross-reactive pH1N1 nucleoprotein (NP) antibodies 5 wk after 
the PR8 infection, and a lower proportion of obese mice generated pH1N1 HAI antibodies 
following the secondary challenge. Consequently, obese mice had greater lung viral titers, more 
lung pathology as well as an increased number of cytotoxic memory CD8
+
 T cells in lung 
airways during the pH1N1 infection. Given the excessive inflammation, infiltration, lung damage 
and cytotoxic CD8
+
 T-cell responses in the lungs of obese mice during the lethal pH1N1 
challenge, we investigated the impact of obesity on regulatory T cells (Tregs) as a potential 
mechanism for the inability to control the antiviral responses in the lung. Unexpectedly, obese 
mice had nearly twice as many Tregs in the lung airways during the heterologous secondary 
pH1N1 infection compared with lean mice. However, ex vivo analysis of Treg function revealed 
that Tregs isolated from obese mice were significantly less suppressive than those isolated from 
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lean mice. Therefore, an excessive inflammatory response in the lungs, potentially due to a 
combination of elevated viral titers and impaired Treg function, may be a mechanism by which 
obesity enhances pH1N1 infection severity.       
 
Materials and methods 
 
Mice and diets  
Weanling, male, C57BL/6J mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME) and fed a low fat diet with 10% kcal fat (Research Diets D12450B) or high fat diet 
with 45% kcal fat (Research Diets D12451, New Brunswick, NJ). In addition to inducing weight 
gain, high fat diets are considered to be pro-inflammatory (191). Mice were maintained on the 
diets for 15-18 wk as described below. Mice were housed in isolation cubicles at the University 
of North Carolina Animal Facility (fully accredited by the American Association for 
Accreditation of Laboratory Animal Care). All experimental procedures involving mice were 
approved by the UNC Institutional Animal Care and Use Committee. 
 
Influenza virus and infection in mice  
Influenza A/Puerto Rico/8/34 (H1N1, PR8), obtained from American Type Culture 
Collection (Manassas, VA), was utilized for primary infections. Pandemic influenza 
A/California/04/09 (H1N1, pH1N1) was obtained from BEI resources (Manassas, VA) and was 
used for secondary infections. Both PR8 and pH1N1 were propagated in the allantoic cavities of 
10-12-day-old embryonated chicken eggs. At 72 h post-infection, allantoic fluid from eggs was 
harvested and clarified by centrifugation at 5000 x rpm for 10 min at 4°C, aliquoted and stored at 
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-80°C. The stock viral titers of PR8 and pH1N1 were determined by a modified 50% tissue 
culture infective dose (TCID50) in Madin-Darby canine kidney cells using hemagglutination as 
an endpoint (79) and evaluated by the method of Reed and Muench (192). For influenza 
inoculations, mice were lightly anesthetized by isoflurane inhalation and inoculated via non-
invasive oral aspiration (193,194) with 0.05mL of viral inoculum diluted in PBS. For re-
challenge studies, mice were maintained on the designated low fat or high fat diet for 15 wk and 
then infected with 11.4 TCID50 PR8 for a primary infection. Mice were monitored and weighed 
daily for 14 days post-infection (dpi) following the primary PR8 infection. Five weeks after the 
primary PR8 infection, a similar period of time as performed by others (78,139,142,195), mice 
were rechallenged with 5x10
3
 TCID50 pH1N1, a previously determined lethal dose 
(approximately 10 LD50).  Following the secondary pH1N1 infection, mice were weighed daily. 
For isolation of Treg cells from mouse splenocytes or harvesting of sera during the primary PR8 
infection, mice were maintained on a high fat or low fat diet for 18 wk. 
 
Quantitation of viral titers  
Viral titers in lung tissue were determined by a modified TCID50 using hemagglutination 
as an endpoint as previously described (196). Briefly, the lung tissue from lavaged mice was 
harvested and frozen in liquid nitrogen for subsequent processing. The supernatant from each 
homogenized lung was collected, serially diluted and added to 80% confluent Madin-Darby 
canine kidney cells in replicates of six in 96-well pates. TCID50 was determined using the Reed 
and Muench method (192), and values were normalized to lung tissue weight (78).   
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Hemagglutination inhibition and microneutralization assays 
Sera were collected from individual mice, at days 0 (five weeks after the primary PR8 
infection, naïve to pH1N1), 5, 8 and 14 following the secondary pH1N1 challenge and 
hemagglutination inhibition (HAI) titers were determined. Briefly, sera were treated with 
receptor destroying enzyme (RDE; Denka Seiken, Tokyo, Japan) overnight, followed by 
inactivation at 56
o
C for 1 h, and a final dilution to 1:10 with PBS. RDE-treated sera were then 
incubated with either pH1N1, PR8 or influenza A/Victoria/361/2011 (negative control) for 15 
min at room temperature (primary PR8 infection sera was incubated with PR8 alone). After a 1 h 
incubation at 4
o
C with either 0.5% turkey RBC (PR8, pH1N1) or 0.5% chicken RBC (PR8, 
A/Victoria/361/2011), HAI titer was determined by the reciprocal of the highest dilution of 
serum to completely inhibit hemagglutination. Positive and negative controls as well as back 
titrations of virus were included on each individual plate.  
Microneutralization assays were performed on sera from PR8-infected mice at 35 dpi as 
previously described (197). Briefly, 100 TCID50 of either PR8 or CA/09 were added to two-fold 
dilutions of RDE-treated sera, and serum-virus mixtures were incubated at 37
o
C, 5% CO2 for 1 h. 
Following incubation, 3 x 10
5
 MDCK cells were added to each well and plates were incubated 
overnight at 37
o
C, 5% CO2. Plates where then fixed with 80% acetone, blocked for 2 hours at 
room temperature and an ELISA was performed using mouse anti-influenza A NP monoclonal 
antibody mixture (BEI Resources) followed by Peroxidase-conjugated goat anti-mouse IgG 
(Jackson Immunoresearch, West Grove, PA). ELISA plates were developed for 10 min using 
Substrate Reagent (R&D Systems, Minneapolis, MN), stopped using a 2N H2SO4 solution and 
absorbance of each well was read at 450nm. Wells were considered positive for 
microneutralization at an OD below or equal to 50% of the MDCK cells being infected. 
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Influenza nucleoprotein ELISA 
Anti-nucleoprotein antibodies in the sera of lean and obese mice 35 days after the 
primary PR8 infection were measured by ELISA. Briefly, 8ug/mL of purified pH1N1 
nucleoprotein (A/California//06/2009, Immune Technology Corp., New York, NY) was coated 
on ELISA plates (BD Falcon, San Jose, CA) overnight at 4
o
C in coating buffer. Influenza 
A/Cal/04/2009 NP was not commercially available, so purified NP from the A/Cal/06/2009 
pandemic strain was used. Subsequently, ELISA plates were blocked with 1% BSA for 1h at 
37
o
C, washed and then incubated with mouse sera (1:400 dilution) overnight. Following the 
overnight incubation, plates were washed and incubated with HRP-conjugated goat anti-mouse 
IgG (Invitrogen, Carlsbad, CA) antibody (1:2000 dilution) for 1h at 37
o
C. After washing, the 
assay was developed with the TMB Substrate Kit (Thermo Scientific, Rockford, IL) per 
manufacturer’s instructions. Optical density was measured at 405nm, and the optical density of 
uninfected control sera was subtracted from the 35 dpi experimental samples.   
 
Lung histopathology 
At 5 dpi, the left lobe of the lung was harvested from lean and obese mice, inflated with 
4% paraformaldehyde and maintained in 4% paraformaldehyde for 48 h, after which samples 
were transferred to 70% ethanol. Tissues were paraffin embedded, and three 5µm (separated by 
100µm) sections (per lung sample) were processed for H&E staining by the UNC Animal 
Histopathology Core Facility. The extent of lung pathology was scored blindly according to 
relative degree of mononuclear infiltrate on a scale from 0 to 4: 0, no inflammation; 1, mild 
influx of inflammatory cells; 2, increased inflammation with ~25-50% of the total lung involved; 
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 3, severe inflammation involving 50-75% of the lung; and 4, almost all lung tissue contains 
inflammatory infiltrate (78). 
 
Bronchoalveolar lavage total protein and albumin measurements  
To recover bronchoalveolar lavage (BAL) fluid, the trachea of killed mice were exposed 
and cannulated with a 22-guage angiocath, and the lungs were then lavaged with a series of 4 
washes with unsupplemented HBSS, totaling 3.75mL (one 0.75mL and three 1mL washes). BAL 
fluid supernatant was collected from the initial 0.75mL lavage and was subsequently used for 
total protein, and albumin detection. The cells from the series of BAL washes for each mouse 
were combined for subsequent flow cytometry analysis. BAL fluid was harvested at 5, 8 and 14 
days following the secondary pH1N1 infection. BAL supernatants from 5 and 8 dpi were diluted 
1:10, and total protein was measured (BCA kit, Sigma Aldrich, St Louis, MO). BAL 
supernatants were diluted 15,000 fold prior to measuring albumin levels per manufacturer 
instructions of the Mouse Albumin ELISA Kit (Genway Biotech, Inc., San Diego, CA). 
      
Quantitation of lung cytokine gene expression 
Lung tissue samples were collected at day 0 (five weeks after the primary PR8 infection, 
naïve to pH1N1) and 5, 8, and 14 days following the secondary pH1N1 infection. Total RNA 
was isolated using the TRIzol method (Invitrogen), and reverse transcription was performed with 
use of the Superscript II First Strand Synthesis kit (Invitrogen) using oligo (dT) primers. 
Expression levels of cytokines and chemokines were quantified using qRT-PCR as previously 
described (79).     
 
35 
 
Flow cytometry  
Splenocytes and cells from draining mediastinal lymph nodes (mLN) were isolated as 
previously described (78). For analysis of surface proteins of T-cell populations, single-cell 
suspensions were simultaneously incubated with Fc blocker (anti-CD16/CD32) and stained in 
PBS (with 1% FBS) with the following monoclonal antibodies: CD3 (APC/Cy7), CD62L 
(Brilliant Violet 421) and CD8 (PerCP) from BioLegend (San Diego, CA); CD4 (FITC, PE-
Cy7), CD25 (PE-Cy7), CCR7 (APC), CD44 (PE-Cy7) and CD62L (E450) from eBioscience 
(San Diego, CA).  MHC class I tetrameric complexes (PE) specific for the H-2D
b
-restricted 
epitope of the nucleoprotein (NP, D
b
NP366-74; ASNENMETM) of PR8 were used to identify NP-
specific T cells and the irrelevant LCMV tetramer D
b
GP33-41 (PE) was used as a negative control 
(NIH Tetramer Core Facility, Atlanta, GA). For intracellular cytokine and transcription factor 
staining, cells were fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer 
Set (eBiosciences) per manufacturer’s instructions. Subsequently, cells were stained with Foxp3 
(APC, eBioscience) for identification of Tregs. For detection of the intracellular cytokines IFN-γ 
(APC, eBioscience) and granzyme B (GzB, FITC, eBioscience), 1-5x10
5
 BAL cells were 
stimulated under the following conditions for 6 h in the presence of Golgi Plug (BD Biosciences, 
San Jose, CA) per manufacturer instructions: incubated with heat-inactivated pH1N1 (inactivated 
by a 1 h incubation at 56°C) at a multiplicity of infection (MOI) of 1x10
-3
; incubated with heat-
inactivated pH1N1 (MOI=2x10
-3
) with antigen-presenting cells (splenocytes from lean mice 
depleted of nonadherent cells) pulsed with heat-inactivated pH1N1 (MOI=0.1) at a ratio of 1 
APC:15 BAL cells; or 0.08 g/mL of Con A. Samples were analyzed on a CyAn ADP Analyzer 
flow cytometer (Beckman Coulter, Inc., Fullerton, CA) and cytometry data were analyzed with 
FlowJo software (TreeStar, Ashland, OR). T-cell populations were analyzed by a doublet 
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exclusion gate for all cells followed by gating of CD3
+
 T cells for further analysis of CD4
+
 and 
CD8
+
 T-cell populations. 
 
Suppression Assay  
Treg suppression assays were performed similar to De Rosa et al. (198). Tregs were 
isolated from pooled splenocytes of three naive lean or three naïve obese mice. CD4
+
CD25
+
 
Tregs and CD4
+
CD25
-
 T effector cells (Teff) were isolated using the Dynabeads FlowComp 
Mouse CD4
+
CD25
+
 Treg Cells kit (Invitrogen) and stimulated with Dynabeads mouse anti-
CD3/28 (0.5 bead/Teff; 5x10
4
 Teff per well). The Treg cells ( 95% Foxp3+ by FACS analysis) 
and Teff cells ( 5% Foxp3+) were cocultured at a ratio of 1:2 in round-bottom 96-well plates 
with complete RPMI medium. Only Teff cells from lean mice were used in the assay to eliminate 
concern of a discrepancy in obese mouse Teff cell proliferation. Cells were stimulated for 72 h, 
and cells were pulsed with [3
H
]thymidine (PerkinElmer, Boston, MA) for the last 16 h of culture. 
Cells were harvested onto glass fiber filter paper (Brandel Inc., Gaithersburg, MD), and 
radioactivity was measured using a Wallac 1409 liquid scintillation counter (Wallac, Turku, 
Finland). 
 
Statistical analysis  
JMP Statistical Software (SAS Institute, Cary, NC) was used for all statistical analyses. 
Statistical significance for parametric data was evaluated using the two-tailed unpaired Student t 
test to compare dietary groups. For nonparametric data, the Wilcoxon signed rank test was used. 
Lastly, for the percentage of mice with HAI titers at each dpi, the 2-tailed Fisher’s exact test was 
used. Differences between means were considered significantly different at p<0.05.   
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Results 
 
Heterologous immune defenses prevent mortality from a lethal pH1N1 challenge in lean 
and obese mice.   
 
To investigate the impact of obesity on heterologous immunity to a lethal pH1N1 
infection, we utilized a diet-induced obese mouse model. To induce obesity, weanling, male 
C57BL/6J mice were fed a high fat (45% kcal from fat) diet or a low fat (10% kcal from fat) 
control diet for 15 wk (Fig. 3.1A). The OpenSource Diets
®
 are composed of purified constituents 
and are matched in every aspect except for fat and carbohydrate content. Mice fed a high fat diet 
rapidly gained more weight than control mice and after 15 wk on the diet weighed approximately 
33% more (Fig. 3.1B). Mice were maintained on the respective high fat or low fat diet 
throughout the course of the experiment, including both primary and secondary infections.   
To test if obese mice had compromised heterologous defenses, lean and obese mice were 
initially infected with a sublethal dose of PR8 virus after the 15 wk of dietary exposure (Fig. 
3.1A). As expected, obese mice lost significantly more weight (5.10±0.40g) compared with lean 
mice (3.54±0.31g) following the primary PR8 infection, but when normalized to pre-infection 
body weight, there were no differences in percent weight loss between lean and obese mice (Fig. 
3.1C). PR8 infected mice were maintained on their respective diets for 5 wk to allow the mice 
sufficient time to recover. After 5 wk, having regained weight equivalent to initial weight status 
prior to the PR8 infection (data not shown), mice were infected with a lethal dose of pH1N1 
virus. One-hundred percent of naïve (unprimed) lean and obese mice rapidly succumbed to the 
lethal pH1N1 infection at 6 dpi (Fig. 3.1D). However, of the mice previously infected with PR8, 
100% of lean mice and 95% of obese mice survived the pH1N1 challenge. Contrary to the initial 
primary infection, both lean and obese mice began to lose weight early at 2 dpi following the 
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secondary pH1N1 infection, with obese mice nearly losing twice as much weight as lean mice 
over the course of the infection. However, once normalized to body weight, weight loss was not 
significantly different between the two groups (Fig. 3.1E).  
 
Diet-induced obesity impairs primary and secondary influenza antibody responses.  
We assayed sera for HAI antibodies 5 wk following the primary PR8 infection in lean 
and obese mice to confirm that the pH1N1 virus was heterologously distinct in our hands. We 
did not detect HAI antibodies to pH1N1 in sera from lean or obese mice previously infected with 
PR8 (Fig. 3.2A). Further, microneutralization assays confirmed that the PR8 infection did not 
induce cross-neutralizing protection to pH1N1 virus (Fig. 3.2B). Similarly, Guo et al. did not 
detect cross-neutralizing antibodies to pH1N1 in sera from PR8-infected mice (133). Therefore, 
reflective of what happened in the human population during the pH1N1 outbreak, PR8 infected 
mice lacked pH1N1cross-reactive neutralizing antibodies. 
As expected, 5 wk after PR8 infection, lean mice displayed elevated HAI and 
microneutralization titers to PR8 but not pH1N1 (Fig. 3.2A/B). Surprisingly, none of the obese 
mice had detectable HAI antibodies to PR8, and obese mice had nearly a 4-fold lower PR8 
microneutralization titer. Although PR8 HAI antibodies are not critical modulators of secondary 
infection outcome in this model, the striking deficiency in PR8 HAI antibodies prompted us to 
measure PR8 antibody levels during the primary PR8 infection to determine if the reduced 
antibody levels at 35 dpi were a result of decreased antibody generation. At 7 dpi following the 
primary PR8 infection, obese mice had a lower mean PR8 HAI titer and a lower percentage of 
obese mice (p=0.06) exhibited detectable PR8 HAI antibodies (Fig. 3.2C/D). However, by 9 dpi 
and through 14 dpi, obese mice had similar levels of HAI antibodies compared with lean mice. 
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Therefore, obese mice exhibited delayed antibody generation during the primary infection but 
were able to compensate and eventually exhibited similar levels to that of lean mice. However, 
by 35 dpi, obese mice did not have any detectable PR8 HAI antibodies (Fig. 3.2C/D), indicating 
that obesity also impairs antibody maintenance. Kim et al. demonstrated that obese mice have 
impaired responsiveness to influenza vaccination, but obesity-induced impairments in antibody 
responses following infection in mice have not previously been shown (68). Interestingly, we 
have similarly demonstrated that obese humans have an impaired ability to maintain long-term 
levels of influenza antibodies (12). 
Because of the striking deficiency of PR8 HAI antibodies in the obese mice at 35 dpi, we 
also assessed pH1N1 HAI antibody levels following the secondary challenge. Previous studies in 
mice have demonstrated that a primary heterologous influenza infection can lead to an 
accelerated production of pH1N1 neutralizing antibodies during a secondary pH1N1 infection 
(137,142), which could potentially impact infection outcome. We did not detect HAI antibodies 
at 5 dpi in lean or obese mice; however, 72.7% of lean mice had HAI antibodies at 8 dpi.  By 14 
dpi, 100% of lean mice had HAI antibodies (Fig. 3.3A/B). In contrast to lean mice, 41.7% of 
obese mice generated detectable serum HAI antibodies at 8 dpi, and only 50% of obese mice had 
pH1N1 HAI antibodies at 14 dpi (Fig. 3.3A/B). Therefore, obese mice displayed altered antibody 
responses during both primary and secondary infections. Although PR8 HAI antibodies offer 
negligible protection during the secondary infection, we measured PR8 HAI antibodies to 
determine if the impairments in antibody production during the secondary infection were specific 
to pH1N1 or a more global defect. The differences between lean and obese mice were striking, as 
75% (day 5), 72.7% (day 8) and 83.3% (day 14) of lean mice had detectable levels of HAI 
antibodies to PR8 during the secondary pH1N1 infection compared with 8.3% (day 5), 16.7% 
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(day 8) and 33.3% (day 14) of obese mice (Fig. 3.3C/D). As a negative control for all HAI titers 
from sera obtained during the secondary infection, influenza A/Victoria/361/2011 (H3N2) was 
assayed in addition to pH1N1 and PR8. Taken together, obese mice exhibited delayed or 
impaired antibody generation during primary and secondary influenza infections, respectively, 
and impaired antibody maintenance (35 days following the primary PR8 infection).  
Although, PR8 antibodies do not neutralize pH1N1 virus infectivity (see Figure 3.2B), 
nucleoprotein (NP) specific antibodies generated during a heterologous primary influenza 
infection or through vaccination have been shown to control virus replication during influenza 
infections (141,199,200). Therefore, we next assayed the level of anti-pH1N1 NP antibodies in 
lean and obese mice at 35 dpi. Interestingly, we detected that obese mice had a significantly 
lower level of serum anti-pH1N1 NP antibodies (Figure 3.3E). Because NP antibodies can 
regulate viral burden (141), we next measured lung viral titers in lean and obese mice to 
determine if lower anti-NP antibody levels potentially impacted influenza viral titers during the 
secondary pH1N1 infection. At 5 dpi, obese mice had greater than a 10-fold higher mean virus 
titer (p=0.05) in the lungs compared with lean mice (Fig. 3.3F). Although viral replication is 
controlled through several cell types and effector responses, it is plausible that reduced NP 
antibody levels resulted in greater viral burden in the lungs of obese mice. 
 
Obese mice develop greater lung airway inflammation following a secondary heterologous 
pH1N1 infection.   
 
Given that obese mice exhibited elevated viral titers at 5 dpi, we next assessed how 
greater viral burden impacted lung inflammation and pathology. Enumeration of BAL cells 
following the secondary infection revealed that obese mice had nearly twice as many cells in the 
lung airways at 5 dpi (Fig. 3.4A). Conversely, in the draining mLN, lean mice had approximately 
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twice as many immune cells as obese mice at 5 dpi (Fig. 3.4B). Despite the lack of differences in 
inflammatory cytokine expression (Table 3.1), obese mice had elevated lung pathology scores 
(Fig. 3.4C) and a greater level BAL fluid protein at 5 dpi (Figure 3.4D). To determine if the 
elevated level of immune cell infiltration and inflammation in the lungs resulted in damage to the 
integrity of the respiratory epithelium in obese mice, we assayed albumin levels in the lung 
airways. Consistent with heightened infiltrate and pathology at 5 dpi, we detected greater levels 
of BAL albumin at 5 dpi in obese mice (Figure 3.4E).  
 
Obese mice have a heightened memory CD8
+
 T-cell response in the lung airways following 
a lethal secondary pH1N1 infection. 
 
The protective role of memory T cells during secondary heterologous influenza infections 
is well established (201,202). Further, several recent investigations have demonstrated that 
exposure to seasonal influenza strains or vaccination can elicit memory T cells that are able to 
recognize viral epitopes of pH1N1, conferring cross-protection (107,137). Both CD4
+
 and CD8
+
 
memory T cells have been shown to be important in limiting disease severity in several models 
of pH1N1 rechallenge studies (133,137,139).  
To determine if obesity influenced the distribution and activation of cross-reactive T 
cells, BAL cells from mice previously infected with PR8 5 wk earlier and then challenged with 
pH1N1 were stimulated with heat-inactivated pH1N1 virus, pH1N1-pulsed APCs or the 
polyclonal mitogen, Con A, at days 5, 8 and 14 following the secondary pH1N1 infection. Figure 
3.5A demonstrates that all three methods of stimulation induced a robust IFN-γ response in 
cross-reactive CD4
+
 T cells at 5 dpi. As expected, the addition of influenza-pulsed APCs in 
culture with BAL cells resulted in an elevated IFN-γ response compared with BAL cells 
incubated with heat-inactivated virus alone. Obesity did not impair IFN-γ or GzB production by 
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memory CD4
+
 T cells in response to the stimuli (Fig. 3.5B/C). There were no differences in 
CD4
+
 T-cell IFN-γ median fluorescence intensity (MFI) or GzB MFI (data not shown). 
Next, we investigated potential differences in CD4
+
 effector memory T cells between 
lean and obese mice as we have previously demonstrated that obese mice have an impaired CD8
+
 
effector memory T-cell response (78). Effector memory T cells were distinguished by lack of 
expression of the cell adhesion molecule, CD62L, which is inherently absent or low on effector 
memory T cells (203). Because we detected differences in viral titers and lung pathology at 5 
dpi, we focused on effector memory T-cell populations specifically on this day. However, we did 
not detect any differences in IFN-γ or GzB production of CD4+CD62L- effector memory T cells 
between lean and obese mice (Fig. 3.5D/E). This suggests, at least partially, that cross-reactive 
CD4
+
 T-cell cytotoxic responses are intact in obese mice.           
We also determined how obesity affected the cross-reactive CD8
+
 T-cell responses under 
the same conditions described for CD4
+
 T cells. Approximately, 4-5% of CD8
+
 T cells from lean 
and obese mice produced IFN-γ following stimulation with influenza-pulsed APCs at 5 dpi (Fig. 
3.6A). After day 5, the magnitude of the CD8
+
 T-cell response declined in both lean and obese 
mice (Fig. 3.6B/C). Interestingly, obese mice had a strikingly elevated number of CD8
+
IFN-γ+ 
and CD8
+
GzB
+
 T cells at 5 dpi (Fig. 3.6B/C). Further analysis of the CD8
+
 memory T-cell 
population revealed that obese mice had an elevated number of CD8
+
CD62L
-
IFN-γ+ T cells and 
a significantly greater number of CD8
+
CD62L
-
GzB
+
 effector memory T cells at 5 dpi as well 
(Fig. 3.6D/E). There were no differences in CD8+ IFN-γ MFI or GzB MFI (data not shown).   
We used whole virus in BAL cell stimulations, and thus we were assessing the total 
polyclonal response of the CD4
+
 and CD8
+
 memory T-cell pool. Since we detected significant 
differences in the number of GzB producing effector memory CD8
+
 T cells in obese mice, we 
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next examined GzB production by effector memory T cells specific for a specified viral epitope. 
As NP from PR8 shares 91% similarity with the pH1N1 NP (142), we used the influenza 
tetramer D
b
NP366-74, allowing for detection of T cells specific for the PR8 NP366-74 epitope during 
the secondary pH1N1 infection. Figure 6F demonstrates that obese mice had a greater number of 
NP336-74 specific T cells producing GzB following stimulation. Further, obese mice had a 
significantly greater number of NP366-74 specific CD8
+
CD62L
-
 T cells, and a significantly greater 
proportion of these cells produced GzB (Fig. 3.6G). The elevated cross-reactive CD8
+
 T-cell 
response could be attributed to the greater viral burden detected in the lungs of obese mice at 5 
dpi. It is likely that greater viral load induced excessive recruitment of CD8
+
 T cells to the lungs, 
and perhaps the elevated CD8
+
 T-cell response was required to control the excess viral burden in 
the absence of proper antibody defenses.    
 
Obese mice have a greater number of CD4
+
CD25
+
Foxp3
+
 Tregs in the lung airways at 5 
dpi.  
 
Numerous factors could contribute to the increased lung inflammation, lung infiltration, 
lung damage and memory CD8
+
 T-cell responses in obese mice. Enhanced inflammatory 
responses in the lungs between 1-5 dpi or altered expression of lung trafficking molecules on 
immune cells could result in the observed differences in infiltration in the lung at 5 dpi. 
However, we did not detect any differences in the percentage of mLN CD8
+
 T cells expressing 
the trafficking molecules CD44, CD62L and CCR7 at 5 dpi, nor did we find any differences in 
mLN or lung chemokine expression at 0 or 5 dpi (mLN data not shown).  
We observed greater infiltration, lung damage and heightened CD8
+
 T-cell responses in 
the lungs of obese mice, and Tregs have been shown to regulate all of these parameters in other 
respiratory infection models (204,205). Further, obesity has been reported to result in a 
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deficiency of anti-inflammatory Tregs in metabolic tissues such as white adipose (206) and the 
liver (207). We therefore proceeded to investigate this unique cell type in the secondary infection 
model as a potential mechanism for increased inflammation in the obese mice. Figure 3.7A 
represents the gating scheme used to distinguish Tregs and demonstrates the Treg distribution in 
the lung airways and mLN in lean and obese mice at 5 dpi. Although, CD25
-
Foxp3
+
 Tregs were 
present in the lung airways and mLN following the secondary infection, the majority of Foxp3
+
 
T cells were CD25
+ 
(Fig. 3.7A). BAL Treg number peaked at 5 dpi in obese mice and 
continually decreased in number, whereas lean mice had consistent numbers of BAL Tregs from 
5 to 8 dpi with a similarly low level of Tregs by 14 dpi (Fig. 3.7B). Interestingly, obese mice had 
more than twice as many BAL Tregs at 5 dpi and nearly half as many mLN Tregs (Fig. 3.7C) 
compared with lean mice. Consistent with two recent publications investigating Tregs during a 
primary influenza infection (208,209), the mLN in lean and obese mice contained a greater 
number of Tregs than the BAL compartment following infection (Fig. 3.7C). There is little 
known regarding memory Tregs during influenza infection nor the distribution and function of 
Tregs during a secondary influenza infection. One would expect a greater presence of 
suppressive Treg cells to result in a dampening of the inflammatory and cytotoxic responses in 
the lungs of obese mice (210). However, we observed the opposite, and therefore investigated 
the possibility that obese mice have impaired Treg suppressive function.  
 
Tregs isolated from obese mice are less suppressive than those from lean mice.  
To compare Treg activity from lean and obese mice, we used a well-established 
suppression assay (198). Tregs isolated from splenocytes were cocultured in the presence of 
CD4
+
CD25
-
 Teff cells isolated from lean mice. Tregs from lean and obese mice were only 
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cocultured with Teff cells isolated from lean mice to eliminate any possibility of a discrepancy in 
Teff proliferation between lean and obese mice. Figure 3.8A demonstrates that isolated Treg 
populations were greater than 95% Foxp3
+
 from both dietary groups, and less than 5% of Teff 
cells isolated from lean mice were Foxp3
+
, confirming pure populations of isolated cells. 
Interestingly, after a 72 h anti-CD3/CD28 polyclonal stimulation, Tregs isolated from obese mice 
were found to be significantly less suppressive (Fig. 3.8B). After normalizing to lean Treg 
activity, Tregs isolated from obese mice were 41% less suppressive (Fig. 3.8C). Therefore, diet-
induced obesity dramatically impaired Treg suppressive activity. There are a wide variety of 
mechanisms that could contribute to the impaired Treg function in obese mice. The level of 
Foxp3 expression in Treg cells is important for suppressive activity as experimental reduction in 
Foxp3 results in impaired Treg suppressive function (211,212). Thus, we assayed Foxp3 protein 
expression levels in Tregs from splenocytes of lean and obese mice, but we did not detect 
differences in Foxp3 levels (Fig. 3.8D) suggesting that impairment in Treg function is due to a 
mechanism unrelated to Foxp3 expression.    
 
Discussion 
 Globally, greater than 1.4 billion adults are overweight, and approximately 500 million of 
these individuals are obese (3). In 2009, obesity was reported to be an independent risk factor for 
hospitalization and death following pH1N1 influenza infection (5-7). Given the prevalence of 
obesity and the consistent threat of influenza epidemics and pandemics, understanding how 
excess adiposity affects the immune response to influenza infection is important in potentially 
developing therapies to limit morbidity and mortality in this at-risk population.  
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 During the 2009 pandemic, a majority of individuals (nonelderly) lacked pre-existing 
neutralizing antibody protection to pH1N1 (102,104-107). Therefore, a number of investigations 
have focused on the protectiveness of heterologous immunity to pH1N1 infection, conferred 
from previous exposure to circulating influenza strains or vaccines (131,139,140). Human 
studies and mouse models have demonstrated that cross-reactive T cells and cross-reactive non-
neutralizing antibody defenses can limit viral load and protect from a lethal heterologous 
influenza infection (102,131,133,142). Additionally, prior heterologous infection can accelerate 
pH1N1 antibody generation during a secondary pH1N1 infection, thus providing an additional 
mechanism by which heterologous immunity can limit pH1N1 infection severity (137,142). 
However, obese humans and mice have been shown to have impaired memory T-cell and 
humoral responses following vaccination or infection (12,68,78,213). Thus, we developed a 
mouse model to investigate if obesity results in enhanced pH1N1 infection severity due to 
impairments in heterologous immune defenses. 
 In this study, obesity did not impair the overall ability of heterologous immunity to 
prevent mortality from pH1N1 infection as 95% of PR8 primed obese mice survived the lethal 
secondary heterologous infection, whereas none of the naïve, obese mice survived the pH1N1 
infection. However, heterologous cellular and humoral responses were significantly altered by 
obesity, and obese mice displayed greater lung damage during the secondary pH1N1 infection. 
Obese mice exhibited a significant delay or impairment in antibody generation during both 
primary and secondary influenza infections. Further obese mice displayed significantly lower 
levels of cross-reactive anti-pH1N1 NP antibodies following the primary PR8 infection. 
Subsequent investigation of viral titers confirmed that obese mice had a greater lung viral titer at 
5 dpi, perhaps due to reduced levels of cross-reactive anti-NP antibodies. Consistent with greater 
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viral load, obese mice had an elevated number of infiltrating cells into the lung airways, 
heightened lung pathology, and greater BAL total protein and albumin levels. Analysis of cross-
reactive T-cell responses demonstrated that obesity led to a heightened CD8
+
 T-cell response in 
the lung airways, but obesity did not impact cross-reactive CD4
+
 T-cell distribution during the 
secondary infection. These data point towards a model in which reduced levels of anti-NP 
antibodies resulted in greater lung viral burden, which subsequently induced greater immune cell 
infiltration, lung damage and heightened CD8
+
 T-cell responses in obese mice. Lastly, we 
investigated the impact of obesity on Treg distribution during the secondary infection model. We 
found that obese mice had a greater number of BAL Tregs at 5 dpi, but ex vivo analysis revealed 
Tregs isolated from obese mice were significantly less functional than Tregs from lean mice. 
Therefore, perhaps obese individuals experienced greater pH1N1 infection severity due to a 
combination of impaired pH1N1 heterologous antibody defenses and excessive antiviral immune 
responses in the lungs, which could not be controlled properly due to dysfunctional Tregs.     
 Despite a lack of neutralizing antibody protection, antibody defenses may still impart 
protection to a lethal pH1N1 infection in our model. A protective role for cross-reactive non-
neutralizing antibodies during influenza infection has been well established (141,142,199,200). 
LaMere et al. demonstrated that intact antibody defenses (i.e. somatic hypermutation and class-
switch recombination) were required for proper heterologous immunity in the classical X31 
prime, PR8 challenge, heterologous infection model (141). Further, influenza NP vaccination or 
passive transfer of NP immune serum can limit viral replication in the lungs of PR8 infected 
mice (141). Therefore, non-neutralizing antibodies can impart antiviral activity, although the 
exact mechanisms by which anti-NP antibodies function remain unclear (141). Interestingly, NP 
was detected in the 2008/09 trivalent inactivated vaccine, and some individuals demonstrated 
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increased levels of anti-NP antibodies following vaccination (200). Therefore, non-neutralizing 
NP antibody protection is clinically relevant as well. The non-neutralizing influenza antibody 
repertoire can also include antibodies targeting other internal viral proteins such as the matrix 
protein (M1) and nonstructural protein 1 (NS1) (141,142). However, the protective role of 
antibodies specific to these proteins is less established and likely less protective compared with 
anti-NP antibodies (141,142). 
Another mechanism by which heterologous immunity may protect against pH1N1 is  
through the acceleration of homologous pH1N1 antibodies produced during a secondary pH1N1 
challenge. A primary heterologous infection followed by a pH1N1 challenge has been shown to 
result in significantly enhanced production of pH1N1 neutralizing antibodies (137), split pH1N1  
antibodies and anti-NP antibodies compared with naïve mice infected with pH1N1 (142). It is 
likely that cross-reactive CD4
+
 T cells facilitate this accelerated homologous pH1N1 antibody 
production (137). We did not detect pH1N1 HAI antibodies at the early time-point of 5 dpi, 
however, we found that a significantly lower proportion of obese mice exhibited detectable 
pH1N1 HAI antibodies 14 days after the secondary challenge. Therefore, it is unlikely that this 
aspect of heterologous immunity contributed to the observed outcomes in lean and obese mice. 
Of particular note, we found that obese mice displayed a delayed production and impaired 
maintenance of PR8 antibodies following the primary, sublethal PR8 infection. Further, obese 
mice had significantly lower mean PR8 HAI titers during the secondary infection, and a lower 
proportion of obese mice had detectable PR8 HAI antibodies at all of the time points assayed. 
Although PR8 HAI antibodies did not mediate protection in this model per se, the dramatic 
impact of obesity on influenza antibody responses has clear public health implications.  Kim et 
al. demonstrated that obesity impairs the antibody response to pH1N1 vaccination in mice (68), 
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but it has not been reported that obesity alters antibody responses during the context of an 
infection.   
 Excessive antiviral and inflammatory immune responses in the lung, contributing to 
severe immunopathology, are known to be one of the primary causes of influenza-related 
morbidity and mortality (214,215). Further, fatal pH1N1 infection is associated with enhanced 
inflammation with high numbers of CD8
+
GzB
+
 cytotoxic T cells and excess local production of 
IFN-γ in the lung (215). We similarly detected greater inflammation, lung pathology and a 
greater number of CD8
+
GzB
+
 cytotoxic T cells in the lungs of obese mice infected with pH1N1. 
Although, only mild symptoms were experienced by a majority of individuals infected, severe 
immunopathology may partly explain why certain at-risk groups, such as obese humans, 
experienced a worse outcome to pH1N1 infection.  
Obesity is characterized by a state of chronic inflammation, likely due, in part, to the 
simultaneous deficiency of Tregs in metabolic tissues (206). Because obesity negatively impacts 
Treg distribution, we hypothesized that obese mice would have fewer Tregs in their lungs, 
offering a potential explanation for the greater lung infiltration, inflammation, pathology, 
damage and the heightened memory CD8
+
 T-cell responses detected in the lung airways at 5 dpi. 
Tregs have been shown to regulate all of these parameters in other respiratory infection models 
(204,205,216).  Contrary to our expectations, we found that obese mice had nearly twice as many 
Tregs in the lung airways at 5 dpi compared with lean mice. Subsequent investigation of Treg 
function revealed that Tregs isolated from obese mice were 41% less suppressive than those 
isolated from lean mice. Therefore, impaired Treg function may have contributed to the 
excessive antiviral responses observed in the lungs of obese mice at 5 dpi. Although, we did not 
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show impaired Treg suppressive function in vivo during the infection, the suppression assay 
suggests that in vivo function may be impaired as well.  
Betts et al. demonstrated that a primary influenza infection results in a robust, antigen-
specific Treg response, and influenza infection-induced Tregs were able to suppress antigen-
specific CD4
+
 and CD8
+
 T-cell proliferation and cytokine production (209). Further, a recent 
study by Brincks et al. reported that during secondary influenza infections, antigen-specific 
memory Tregs exhibit accelerated accumulation in the lungs and mLN compared with primary 
infection responses and control memory CD8
+
 T-cell proliferation in a MHC class II dependent 
antigen-specific manner (217). Interestingly, depletion of memory Tregs resulted in heightened 
CD8
+
 T-cell responses, pulmonary inflammation and lung cytokine expression during a 
secondary influenza infection (217). It is possible that obesity-induced alterations in memory 
Treg responses could have contributed to the aberrant inflammatory responses observed in obese 
mice during the secondary pH1N1 infection. 
We utilized a mouse model of diet-induced obesity and heterologous influenza infection 
in attempt to mirror clinical and epidemiological evidence. We found lower levels of non-
neutralizing influenza NP antibodies, heightened cross-reactive CD8
+
 T-cell responses, greater 
viral titers and lung pathology, and impaired Treg function in obese mice. We propose that 
impaired antibody protection resulted in greater viral burden, which subsequently drove 
heightened inflammatory responses that were not properly controlled by dysfunctional Tregs. 
This study and numerous others have demonstrated obesity negatively impacts the immune 
response to influenza infection (67,68,78,79,81,82,213). Yet, the exact cellular and molecular 
mechanisms by which excess adiposity contributes to altered antiviral defenses remain unclear 
(2). It is possible that one global defect in all immune cells can explain impaired functionality in 
51 
 
the obese, but it is more likely that a complex combination of altered signaling pathways and 
responses ultimately impairs immunity and results in greater influenza susceptibility (2).      
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Tables and Figures 
 
 
Table 3.1 Similar levels of lung cytokine and chemokine expression during a secondary 
heterologous pH1N1 challenge in lean and obese mice 
 
 
 
Table 3.1: Values represent mean fold increase over uninfected control ± SEM (n=4-6), *p<0.05 
compared with 0 dpi within same dietary group. There were no statistical differences between 
lean and obese mice at any time point. 
 
 
 
 
 
 
 
 
 
Gene 
Dietary 
Group Day 0 Day 5 Day 8 Day 14 
TNF-α 
Lean 1.00±0.11 1.92±0.44 0.89±0.12 1.12±0.10 
Obese 0.83±0.09 2.20±0.51* 0.78±0.09 0.84±0.12 
IL-1β 
Lean 1.00±0.11 1.75±0.29* 0.69±0.10 0.59±0.07* 
Obese 3.07±1.13 2.64±0.57 0.59±0.10* 0.53±0.08* 
IFN-  
Lean 1.00±0.32 6.33±0.69* 2.41±0.29* 1.96±0.10 
Obese 0.71±0.15 6.58±1.69* 2.01±0.19* 1.81±0.11* 
IL-10 
Lean 1.00±0.18 6.62±0.83* 2.84±0.29* 0.94±0.05 
Obese 1.11±0.34 8.31±5.09 4.09±0.69* 1.40±0.42 
RANTES 
Lean 1.00±0.51 0.69±0.08 1.08±0.20 0.64±0.20 
Obese 0.48±0.0.08 0.73±0.15 0.76±0.09 0.79±0.15 
MCP-1 
Lean 1.00±0.11 14.25±1.34* 1.32±0.18 0.77±0.05 
Obese 0.73±0.01 23.99±7.49* 2.20±0.83* 0.86±0.11 
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Figure 3.1 Sublethal influenza A/PR/8/34 infection induces heterologous protection against 
a lethal pH1N1 challenge in lean and diet-induced obese mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: A, Weanling, male C57BL/6J mice were placed on a high fat or low fat, control diet 
for 15 wk. Lean and obese mice were infected with a sublethal dose of influenza A/PR/8/34. 
Thirty-five days after the primary infection, mice were challenged with a lethal dose of pH1N1 
and samples were harvested at day 0 (naïve to pH1N1), and 5, 8 and 14 dpi. B, Mice fed a high 
fat diet gain significantly more weight than mice fed a low fat, control diet (n 40 per group). 
After one week and throughout dietary exposure, high fat diet fed mice weigh significantly more 
than low fat diet fed mice. C, Fifteen weeks after mice were placed on the designated diets, mice 
were inoculated with a sublethal dose of PR8, and weight loss was monitored daily. D, Five 
weeks after the primary PR8 infection, PR8 primed (two cohorts of n=46) and naive mice (n=3-
4) were challenged with a lethal dose of pH1N1. The naïve mice rapidly succumbed to the 
pH1N1 challenge, whereas primed mice did not. E, Secondary pH1N1 infection weight loss. 
Diet-induced weight gain graphs and infection weight loss graphs represent means   SEM of at 
least two independent experiments. *p<0.05 compared with obese mice. 
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Figure 3.2 Obese mice exhibit delayed antibody production and impaired antibody 
maintenance following a sublethal PR8 infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: A and B, HAI (A) and microneutralization (B) titers of sera from lean and obese 
mice 5 wk after a primary PR8 infection, demonstrating that PR8 does not elicit a cross-
neutralizing pH1N1 antibody response (n=9-10). C and D, PR8 HAI titer (C) and percentage of 
mice with detectable PR8 HAI antibodies (D) following a sublethal PR8 infection (n=8-11). The 
limit of detection for HAI and microneutralization titers is 10. Each data point represents an 
individual animal. Bars represent mean HAI   SEM or percentage of mice with detectable PR8 
HAI. *p<0.05, **p<0.005, ***p<0.0005. 
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Figure 3.3 Obese mice have lower levels of cross-reactive anti-pH1N1 nucleoprotein 
antibodies and exhibit greater lung viral titers during a secondary pH1N1 infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: A and B, Serum pH1N1 HAI titer (A) and percentage of mice with detectable 
pH1N1 HAI antibodies (B) during a secondary heterologous pH1N1 challenge, n=10-12. C and 
D, Serum PR8 HAI titer (C) and percentage of mice with detectable PR8 HAI antibodies (D) 
during a secondary heterologous pH1N1 challenge, n=10-12. The limit of detection for HAI 
titers is 10. E, Obese mice have lower levels of serum cross-reactive anti-pH1N1 NP antibodies 5 
wk after a primary PR8 infection, n=9-10. F, Obese mice have a greater viral burden at 5 dpi 
during the pH1N1 rechallenge (n=12). No virus was detected (N.D.) at 0 or 8 dpi, n=5-6 at 0 and 
8 dpi. Each data point represents an individual animal. Bars represent percentage of mice with 
detectable HAI antibody or mean viral titer   SEM. *p<0.05, **p<0.005 compared with lean 
mice.      
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Figure 3.4 Obese mice exhibit a greater inflammatory and pathological response in the 
lungs following a secondary heterologous pH1N1 challenge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: A and B, Enumeration of BAL cells (A) and mLN cells (B) at 5, 8 and 14 dpi 
following the secondary pH1N1 challenge, n=9-12. Each data point represents an individual 
animal. C, Representative H&E stained lung histology slides at 40x and 100x magnification and 
pathology score at 5 dpi, n=3-4. D, Total protein in BAL fluid at 5 and 8 dpi, n=5-6. E, Albumin 
levels in BAL fluid at 5 and 8 dpi, n=5-6. Bars represent mean   SEM, *p<0.05, **p<0.005 
compared with lean mice. 
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Figure 3.5 Exposure to PR8 elicits a rapid and robust memory CD4
+
 T-cell response 
following pH1N1 infection in both lean and obese mice 
 
 
 
 
 
 
 
 
 
Figure 3.5: BAL cells from mice challenged with a secondary heterologous pH1N1 infection 
were stimulated for 6h with heat-inactivated pH1N1 (n=5-6), pH1N1 pulsed APCs (n=4-6) or 
Con A (n=5-6). A, Representative flow cytometry gating scheme at 5 dpi, including mean % 
(SEM). B and C, Number of IFN-γ (B) and GzB (C) producing CD4+ T cells after stimulation 
with pH1N1 pulsed APCs, n=4-6. D and E, Number of IFN-γ (D) and GzB (E) producing 
effector memory CD4
+
 T cells after stimulation with pH1N1 pulsed APCs at 5 dpi, n=4-6. Each 
bar represents the mean   SEM. 
 
 
 
 
 
 
  
5
8
 
Figure 3.6 Obese mice have enhanced cross-reactive CD8
+
 T-cell responses at 5 dpi after a secondary heterologous pH1N1 
challenge 
FIGURE 3.6: A, BAL cells from mice challenged with a secondary heterologous pH1N1 infection were stimulated as described in the 
legend to Figure 4. A, Representative flow cytometry gating scheme at 5 dpi, including mean percentage (SEM), n=4-6. B and C, 
Number of IFN-γ (B) and GzB (C) producing CD8+ T cells after stimulation with pH1N1 pulsed APCs, n=4-6. D and E, Number of 
IFN-γ (D) and GzB (E) producing effector memory CD8+ T cells after stimulation with pH1N1 pulsed APCs at 5 dpi, n=4-6. F, 
Enumeration of GzB producing, NP366-74 specific CD8
+
 T cells  in the BAL compartment, n=4-6. G, Comparison of GzB production 
by NP-specific effector memory CD8
+
 T cells stimulated with APCs at 5 dpi,  n=4-6. Each bar represents the mean   SEM, *p<0.05 
compared with lean mice at 5 dpi.  
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Figure 3.7 Obese mice have a greater number of Tregs in the lung airways during a 
heterologous secondary pH1N1 challenge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: A, Representative BAL (n=5-6) and mLN (n=10-12) CD4
+
CD25
+
Foxp3
+
 Treg 
gating scheme at 5 dpi, including mean percentage (SEM). B and C, Enumeration of Tregs in 
BAL fluid (B) and mLN (C). Each bar represents the mean   SEM, and *p<0.05 compared with 
lean mice at 5 dpi. 
 
60 
 
Figure 3.8 Tregs isolated from obese mice are significantly less suppressive than Tregs 
isolated from lean mice 
 
 
Figure 3.8: Pooled CD4
+
CD25
-
 Teff cells and CD4
+
CD25
+
 Tregs were isolated from 
splenocytes of naïve lean (n=3) and obese mice (n=3). A, Greater than 95% of isolated Tregs 
expressed Foxp3 from lean and obese mice, and less than 5% of Teff cells expressed Foxp3 as 
determined by FACS analysis, confirming pure populations of cells. B, Suppression assay 
comparing functionality of lean Tregs and obese Tregs cocultured with lean Teff cells at a ratio 
of 1:2 in the presence of anti-CD3/CD28 for 72 h. C, Normalized suppressive activity of isolated 
Tregs. D, Foxp3 median fluorescence intensity (MFI) of Tregs from splenocytes of lean and 
obese mice. Each data point represents an individual animal, n=5-6. Each bar represents the 
mean   SEM, and *p<0.05 compared with lean mice. 
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CHAPTER IV: DIET- AND GENETIC-INDUCED OBESITY RESULTS IN GREATER 
LUNG DAMAGE AND MORTALITY DURING A PRIMARY 2009 PANDEMIC  
H1N1 INFLUENZA VIRUS INFECTION IN MICE 
 
Introduction 
The triple reassortant H1N1 influenza virus, responsible for causing the 2009 influenza 
pandemic outbreak, continues to circulate and cause epidemics globally (218). The 2009 
pandemic H1N1 strain (pH1N1) was novel in several aspects. Despite infecting up to 89 million 
people in the US alone (16), pH1N1 infection symptoms were relatively mild (13,99). However, 
certain at risk groups exhibited greater morbidity and mortality following infection, including 
individuals with underlying health conditions such as asthma, type 2 diabetes, COPD, smokers 
and pregnant women (4,13,15). Further, several epidemiological investigations identified obesity 
as an independent risk factor for hospitalization and death to pH1N1 infection (72-75). Globally, 
more than 500 million individuals are obese (BMI≥kg/m2) (3). Therefore, understanding the 
mechanisms by which obesity drives greater pH1N1 infection severity is critical for solving this 
widespread global public health issue and will ultimately facilitate identification of novel 
vaccination or therapeutic approaches.  
Vaccination is considered the best available measure for preventing infection and limiting 
influenza severity (219). We have previously demonstrated that obese humans exhibit impaired 
influenza vaccination responses. Following trivalent influenza vaccine (TIV) immunization, 
circulating memory T cell activation induced by vaccine strains was impaired in obese 
individuals (BMI≥30) compared with healthy weight adults (11,12). Although short term TIV 
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antibody responses are intact, obese individuals displayed a greater decline in influenza 
antibodies one year after vaccination (12). At this point in time, it is not clear whether obese 
individuals are more susceptible to influenza infection, only that illness is more severe in those 
infected.  
Similar to obese humans, obese mice exhibit greater mortality from influenza infection 
compared with lean control mice (2). It is well established that obesity alters inflammatory 
responses and the function of a variety of innate and adaptive immune cell populations (2). 
Further, during the context of influenza infection, obese mice exhibit heightened inflammatory 
responses in the lung, impaired lung epithelial wound healing, blunted antibody responses and 
aberrant memory T cell responses (14,67,68,78,82). However, the underlying cellular and 
molecular mechanisms for greater influenza mortality in obese mice remain unclear. Excess 
adiposity triggers a number of metabolic and physiologic perturbations such as insulin resistance, 
hyperleptinemia, greater oxidative stress, low-grade chronic inflammation and alterations in a 
variety of circulating nutrients and hormones, all of which could potentially affect influenza 
immunity (2).  
Herein, we demonstrate that high fat diet (HFD) induced obese mice are more susceptible 
to intranasal pH1N1 infection compared with lean, low fat diet (LFD) fed and lean, chow diet 
(CD) fed mice. For the first time, we also demonstrate that mice fed a purified LFD exhibit 
greater pH1N1 mortality compared with CD fed mice. We then explored the impact of obesity 
(independent of diet) on pH1N1 infection severity. A genetic model of obesity was used, wherein 
leptin signaling was disrupted in hypothalamic neurons, providing a robust model of obesity 
independent of HFD effects. Similar to diet-induced obesity, genetic-induced obesity resulted in 
greater pH1N1 mortality.  
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Analysis of infection responses revealed that diet and genetically-induced obese mice had 
relatively similar levels of lung immune cell infiltration, lung pathology, inflammatory 
cytokines, and virus titers despite a striking difference in mortality compared with lean control 
mice. However, both models of obesity exhibited greater lung airway damage during pH1N1 
infection compared with lean controls. Analysis of immune cells resident in the bronchoalveolar 
compartment revealed that obese mice had fewer macrophages but similar numbers of 
neutrophils and NK cells. Further, obese mice had fewer activated regulatory T cells in the lung 
airways during infection. Of interest, we have previously demonstrated that Tregs isolated from 
obese mice exhibit impaired suppressive function (14).  
We next addressed the immunomodulatory role of leptin during the context of pH1N1 
infection in obese mice. Obesity is characterized by a state of hyperleptinemia, and it has 
previously been demonstrated that leptin antibody treatment during pH1N1 infection limits 
infection mortality in obese mice (82). Further, leptin is a critical regulator of effector and 
regulatory T cell responses (220). In our study, both diet and genetic models of obesity exhibited 
hyperleptinemia prior to and during the pH1N1 infection. We also detected a greater 
concentration of leptin in the lung airways of obese mice during pH1N1 infection. We then 
investigated if disruption of leptin signaling in T cells (LepR
T-/-
) ameliorates infection severity in 
obese mice. LepR
T-/-
 and LepR
Tfl/fl
 mice (fully floxed, littermate control mice) were maintained 
on a high fat diet or standard chow diet for approximately 15 wks, with no differences in weight 
gain between LepR
T-/-
 and LepR
Tfl/fl
 mice. Subsequently, mice were infected with pH1N1, and as 
expected obese LepR
Tfl/fl
 mice exhibited greater mortality than lean LepR
Tfl/fl 
mice. However, 
there were no differences in mortality between obese LepR
Tfl/fl 
and obese LepR
T-/-
 mice. 
Therefore, pH1N1 mortality is not likely mediated by leptin signaling in T cells. 
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Materials and methods 
 
Mice and diets 
Diet-induced obesity was achieved by maintaining weanling, male C57BL6/J mice 
(obtained from The Jackson Laboratory, Bar Harbor, ME) on a HFD (60% kcal fat, Research 
Diets D12492, New Brunswick, NJ), and lean mice were maintained on a LFD (10% kcal fat, 
35% kcal sucrose, 
Research Diets D12450B) or a standard CD (14.02% kcal fat) for approximately 15 
weeks. Genetically-induced obesity was achieved by crossing fully floxed leptin receptor mice 
on a C57BL6/J background (generously provided by Alyssa Hasty) with C57BL/6J-Tg(Nkx2-1-
cre)2Sand/J mice purchased from the Jackson Laboratory. Fully floxed mice expressing the Cre 
transgene under control of the Nk2.1 promoter, lack leptin receptor signaling in hypothalamic 
neurons (LepR
H-/-
) and become obese due to hyperphagia (221). Additionally, LepR
H-/-
 mice do 
not breed properly; therefore LepR
H+/-
 and LepR
Hfl/fl
 (fully floxed leptin receptor) mice were 
used for breeding (221).  
Disruption of leptin signaling in T cells was achieved by crossing fully floxed leptin 
receptor mice with B6.Cg-Tg(Lck-cre)548Jxm/J (expressing Cre under control of the 
Lymphocyte-specific protein tyrosine kinase, Lck, promoter)  mice purchased from the Jackson 
Laboratory. For obesity studies, mice lacking leptin receptor signaling in T cells (LepR
T-/-
) and 
littermate control fully floxed mice (LepR
Tfl/fl
) were maintained on a high fat diet (60% kcal fat, 
Research Diets D12492) or a standard chow diet for 15-17 wks.  
Hypothalamic and T cell leptin receptor conditional knockout mice were genotyped as 
previously described (221). Mice were housed in isolation cubicles at UNC, which is fully 
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accredited by the American Association for Accreditation of Laboratory Animal Care. All 
procedures involving the use of mice were fully approved by the UNC Institutional Animal Care 
and Use Committee.  
 
Influenza virus infection and viral titers 
Influenza A/Cal/04/09 (BEI Resources, Bethesda, MD) was propagated in embryonated 
hen’s eggs and titered via a modified TCID50 using hemagglutination as an endpoint as 
previously described (2,78). Mice were lightly anesthetized via isoflurane inhalation and were 
infected intranasally with 5.8x10
2
 TCID50 or 1.3x10
3
 TCID50 as described in figure legends. For 
influenza viral titers of infected mice, BALF was titered via a modified TCID50 in replicates of 
four.   
 
Serum and BALF measurements 
BALF was obtained as previously as previously described (14). Serum and BALF leptin 
were measured with use of an ELISA kit per manufacturer’s instructions (Invitrogen, Carlsbad, 
CA). ELISA kits were used to measure serum TAG (Pointe Scientific, Canton, MI) and 
adiponectin (Abcam, Cambridge, UK). Further, BALF albumin was measured with the Mouse 
Albumin ELISA Kit (Genway Biotech, Inc., San Diego, CA). Total protein in BALF was 
measured via standard BCA assay (BCA kit, Sigma Aldrich, St Louis, MO). BALF cytokines 
(IL-4, IFNγ, MCP-1, RANTES, KC, IL-17A, IL-10 and TNFα) were measured via a BioRad 
Bio-Plex assay per manufacturer’s instructions (Hercules, CA).  
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Lung Histopathology 
The left lobe of the lung was inflated and fixed with 10% neutral buffered formalin. 
Fixed lung was embedded in paraffin and processed for H&E staining by the UNC Animal 
Histopathology Core Facility. Lung pathology was blindly scored from 1-4 based on varying 
degree of immune cell infiltration and inflammation as described previously (78). 
 
Flow Cytometry 
Lungs, spleen, mLN and BAL cells were stained for flow cytometry as previously 
described. For staining of BAL cells from uninfected mice, samples were pooled from 2 
individual mice to obtain a sufficient number of cells. The following antibodies were used: CD4 
(FITC, PE-Cy7), CD103 (PE), Foxp3 (APC), Ly6G (FITC), NK1.1 (PE-Cy7) and F4/80 (APC) 
from EBioscience (San Diego, CA) and CD8 (PerCP) and CD3 (APC-Cy7) from BioLegend 
(San Diego, CA) and CD25 (FITC) from BD Biosciences (Sam Jose, CA). For intracellular 
staining, all cells were fixed and permeabilized using the Foxp3 staining buffer kit (Ebioscience). 
All samples were run on a CyAn ADP Analyzer flow cytometer (Beckman Coulter, Inc., 
Fullerton, CA) and analyzed with FlowJo software (Treestar, Ashland, OR).   
 
Statistical analysis 
For all statistical analyses, JMP Statistical Software (SAS Institute, Cary, NC) was used. 
For parametric data, statistical significance was evaluated using a two-way ANOVA or a two-
tailed unpaired Student t test. Nonparametric data was evaluated using the Wilcoxon signed rank 
test or Kruskal Wallis test.  Mean values were considered statistically significant at p≤0.05. The 
log-rank test was used to compare percent survival.    
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Results 
 
High fat and low fat diet fed mice are more susceptible to pH1N1 infection compared with 
chow fed mice 
 
In studying diet-induced obesity in mice, careful consideration of the low fat control diet 
of lean mice is essential to limiting introduction of confounding factors. In diet-induced obesity 
models, a standard control for a HFD is a 10% kcal derived from fat, purified LFD, matched in 
every aspect except fat and carbohydrate content. However, standard CD are derived from 
unpurified plant constituents, often of variable types and quantities, resulting in the presence of 
dietary fiber, phytoestrogens and varying levels of micronutrients compared with the 
experimental high fat diet (66,69). However, purified LFD (69) or high sucrose diets (70) have 
been shown to induce metabolic disturbances and cause mild glucose intolerance. Therefore, in 
this study we used two dietary controls for lean mice, both the 10% kcal fat LFD and a standard 
CD.     
Weanling, C57BL6/J mice were maintained on a HFD (60% kcal fat), a LFD (10% kcal 
fat) or a standard CD (14.3% kcal fat) for 15 wks. As expected, mice fed a HFD gain 
significantly more weight and become obese compared with LFD and CD fed mice (Figure 
4.1A). Although LFD and CD mice exhibited relatively similar levels of weight gain in 
comparison with obese mice, LFD mice weighed significantly more than CD mice after 8 wks on 
the diet (p<0.005). Obesity induces a state of insulin resistance, resulting in hyperglycemia (1). 
Obese mice had elevated fasting blood glucose levels compared with LFD and CD mice, 
consistent with glucose intolerance (Figure 4.1B). Further, non-fasted serum triacylglycerol was 
elevated in obese mice compared with LFD mice (Figure 4.1C), and adiponectin concentration 
was lower in obese mice compared with CD mice (Figure 4.1D). Leptin is an anorexigenic and 
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immunomodulatory hormone primarily produced from adipocytes, and as adiposity increases, 
circulating leptin levels also increase. The serum leptin level of obese mice reached nearly 
80ng/mL, LFD mice had an intermediate leptin concentration of 50ng/ml and CD mice had the 
lowest concentration of approximately 20ng/mL (Figure 4.1E). In summary, HFD mice exhibited 
prototypical characteristics of obesity, while LFD mice exhibited a slightly intermediate 
phenotype compared with HFD and CD mice. 
Following the 15 wk dietary exposure, mice were infected with 5.8 x 10
2
 TCID50 of the 
2009 pandemic strain, influenza A/Cal/07/09 (H1N1, pH1N1). Strikingly, while no CD mice 
succumbed to the pH1N1 infection, 40% of LFD mice and more than 80% of obese mice died by 
10 dpi (Figure 4.1F). Obese mice exhibited a significantly higher mortality rate compared with 
both LFD and CD mice. Although it has been shown that obese mice are more susceptible to 
pH1N1 (67), it has never been demonstrated that LFD fed mice are also more likely to die from 
influenza infection compared with CD mice. Analysis of weight loss demonstrated that CD mice 
recover faster from the infection compared with obese and LFD mice (Figure 4.1G). Because 
obese mice weigh more compared with the lean groups, we also included total weight loss in our 
analysis, which revealed that obese mice lost greater absolute weight compared with both lean 
groups (Figure 4.1H).  
Given that all CD mice survived the infection, we extended our analysis to determine if 
the discrepancy in pH1N1 mortality is maintained with a greater pH1N1 dose. All three dietary 
groups were infected with 1.3 x 10
3
 TCID50 (a 3.5 fold increase in dosage), and by 7 dpi 100% of 
obese mice died (Figure 4.1I). Further, 100% of LFD mice died by 8 dpi, and 80% of CD mice 
died by 9 dpi. Despite the enhanced death in all three groups compared with the previous dose, 
the mortality differences between the dietary groups were relatively maintained in that LFD and 
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obese mice were more susceptible compared with CD mice (p<0.005) and obese mice were 
nearly more susceptible compared with LFD mice (p=0.08). Of interest, obese mice displayed a 
significantly lower percent weight loss over the course of the more severe infection compared 
with LFD and CD mice (Figure 4.1J). However, this is because obese mice weighed nearly 40% 
compared with the lean groups; there were no differences in the total amount of weight lost 
(Figure 4.1K)   
 
Obesity, independent of diet, increases pH1N1 susceptibility 
It is apparent that obese mice exhibit greater pH1N1 infection severity. Unexpectedly, 
LFD mice also display greater mortality compared with CD mice, although not to the same 
extent as obese mice. This brings into question what the proper dietary control group is for 
infection comparisons, and if the differences in pH1N1 severity are mediated by obesity or diet 
(or perhaps both). Although it is intriguing that LFD mice exhibit greater pH1N1 mortality 
compared with CD mice, the focus of this study is to decipher mechanisms by which obesity 
enhances pH1N1 severity. One critical question that remains to be addressed thus far is whether 
obesity is responsible for the observed infection outcomes, or if the discrepancy in infection 
responses is simply due to modifying the diet of the mice.  
To address the immunomodulatory impact of obesity on pH1N1 infection responses, 
independent of dietary changes, we utilized a genetic model of obesity in which excess adiposity 
is driven primarily by hyperphagia (all mice are fed a CD). It has previously been shown that 
ob/ob mice, a robust model of genetic obesity, are more susceptible to pH1N1 infection 
compared with wild type mice. However, utilization of the ob/ob mouse model has several 
limitations due to the global deficiency of leptin signaling. Leptin is critical for proper 
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physiology and immunity, and leptin deficiency can negatively impact host defenses, thus, 
confounding the effects of a obesity (14). Therefore, we used a tissue-specific model, previously 
characterized by Ring et al., in which disruption of leptin signaling is limited to hypothalamic 
neurons (the primary site of leptin-mediated appetite control) (221) to further address the impact 
of obesity on pH1N1 immunity.  
Male and female LepR
H-/-
 mice, lacking functional leptin receptors in hypothalamic 
neurons, rapidly gain excess body weight compared to lean LepR
Hfl/fl
 and LepR
H+/-
 mice (Figure 
4.2A/2B). At 13-16 wks of age, LepR
H-/-
, LepR
H+/-
, and LepR
Hfl/fl
 mice were infected with 5.8 x 
10
2
 TCID50 pH1N1 (the identical dose utilized in Figure 4.1F). Following the infection, obese 
male and female LepR
H-/-
 mice were significantly more susceptible compared with lean LepR
H+/-
 
and LepR
Hfl/fl
 mice (Figure 4.2C/2D). Obese male and female LepR
H-/- 
displayed a strikingly 
lower percentage of body weight lost compared with lean mice Figure (4.2E/3F). However, this 
is due to the greater pre-infection weight in LepR
H-/-
 because the LepR
H-/-
 mice lost a greater 
amount of weight compared with lean groups (Figure 4.2G/H). There were no differences in 
mortality between male and female LepR
H-/-
 mice; therefore, for further analyses, male and 
female mice were combined. Also, there was no statistically significant difference in mortality 
between diet-induced obese mice and genetically obese mice. 
 
Diet-induced obesity does not modulate lung pH1N1 viral burden 
To assess potential mechanisms for the discrepancies in pH1N1 mortality between 
dietary groups, we first measured the level of viral burden in the lung airways of the three dietary 
groups CD, LFD and HFD (from Figure 4.1). There were no differences in viral titers among the 
three groups at 4 or 8 dpi (Figure 4.3A). While some studies report greater viral titers in obese 
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mice (80), others have shown obesity does not impact viral burden (67,77). We then assessed the 
level of cellular infiltration and lung pathology during the pH1N1 infection. HFD, LFD and CD 
mice exhibited similar levels of total bronchoalveolar lavage (BAL) cell numbers (Figure 4.3B) 
and total lung cell numbers (Figure 4.3C). Cytokine and chemokine production in the lung 
airways of the three dietary groups was also measured (Table 4.1 and Figure 4.3D). Figure 4.3D 
is a heat map demonstrating that while global changes in cytokine concentration over the course 
of infection are evident, the level of changes among the dietary groups within each dpi was 
relatively minimal. Obese mice had elevated levels of keratinocyte chemoattractant (KC or 
CXCL1) compared with LFD and CD mice at 8 dpi (Table 4.1). TNFα and MCP-1 were greater 
at 4 dpi in HFD mice compared with LFD, and IL-17A was greater at 8dpi in HFD mice 
compared with LFD mice. Although IFNγ was elevated in obese mice at 8 dpi, it was not 
significantly different from the lean groups. There were no differences in the level of IL-10, 
RANTES between the dietary groups, and IL-4 was below the level of detection. Taken together, 
obese mice exhibited minor differences in lung inflammatory responses, despite striking 
differences in infection mortality. 
 
Diet-induced obesity enhances lung airway damage during pH1N1 infection 
Total protein level in BALF is a classical measurement of damage to the alveolar-
endothelial barrier. At 4 dpi, HFD mice exhibited a greater fold increase in BALF protein levels 
compared with LFD and CD mice (Figure 4.3E). Further, at 8 dpi, HFD mice displayed a greater 
fold increase in BALF protein compared with CD mice. Additionally, we measured BALF 
albumin concentration. Obese mice exhibited a greater fold increase in BALF albumin compared 
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with LFD and CD mice at 4 dpi (Figure 4.3F). Therefore, obesity enhances lung airway damage 
during pH1N1 infection.  
We next addressed the impact of obesity on lung histopathology during pH1N1 infection. 
As expected, H&E stained lungs revealed that pH1N1 infection caused distinct pathological 
changes in the bronchioles of all three dietary groups (Figure 4.4A). At 4 dpi, partial bronchiole 
denuding and perivascular cuffing occurred in all three dietary groups compared with uninfected 
lungs. Additionally, the width of the bronchiole walls also increased compared with uninfected 
mice. By 8 dpi, the level of perivascular cuffing, bronchial denuding and immune cell infiltration 
increased in all three dietary groups compared with the day 4 time point. By 8 dpi, the total level 
of infiltration increased in all three groups, and LFD and HFD tended to have a greater level of 
diffuse infiltration in alveoli, but with minimal thickening of alveolar walls. Further, CD fed and 
LFD mice exhibited greater thickening of the bronchus wall at 8 dpi. Of interest, the bronchus 
wall in HFD mice appeared much thinner at 8 dpi compared with infected CD and LFD mice and 
with uninfected lean controls. Although we observed several interesting pathological features 
among the three dietary groups during pH1N1 infection, histopathology scores of total lung 
infiltration and inflammation revealed there were no significant differences among the three 
dietary groups (data not shown), consistent with no differences in total lung cell number. 
 
Obese mice have fewer macrophages in the lung airways compared with lean mice. 
In order to gain a better understanding for the greater lung damage in obese mice, we 
assessed the distribution of relevant innate immune cells in the lung airways of pH1N1 infected 
CD and HFD mice. We decided to focus on CD and HFD given the striking differences in 
mortality. Figure 4.5A is a representative flow cytometry gating scheme demonstrating how 
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macrophages, neutrophils and natural killer (NK) cells were identified. Figure 4.5B represents 
the percentage of F4/80
+
 macrophages detected in the lung airways of CD and HFD mice at 4 
and 8 dpi, and Figure 4.5C is the total number of macrophages. Unexpectedly, obese mice had 
significantly fewer BAL macrophages at 4 dpi. Figure 4.5D and E demonstrate that obesity did 
not alter BAL neutrophil percentage or number during the infection. Lastly, Figures 4.5F/G 
demonstrate that obese mice had a lower percentage of NK cells at 4 dpi, but not a statistically 
different number of NK cells at 4 dpi.  
 
Obese mice have fewer Treg cells in the lung airways during pH1N1 infection. 
We next assessed T cell responses in the lungs of CD and HFD mice. There were no 
differences in CD8
+
 T cell numbers in the lung airways, but obese mice had fewer CD4
+
 T cells 
at 8 dpi (Figures 4.6A/6B). Although CD8
+
 T cells are classically considered to be primary 
mediators of controlling viral replication during influenza infection, effector CD4
+
 T cells also 
facilitate viral clearance. However, we did not detect differences in viral replication between CD 
and HFD fed mice (Figure 4.3A).  
Recently, CD4
+
Foxp3
+
 Tregs have been shown to modulate respiratory inflammatory 
responses to RSV and influenza virus infection in mice (205,216,222). Because we detected 
fewer CD4
+
 T cells in obese mice, we also suspected fewer BAL Treg cells as well, perhaps 
contributing to heightened lung airway damage in obese mice. Figure 4.6C is a representative 
gating scheme for identification of BAL Tregs in CD and HFD mice. Consistent with fewer 
CD4
+
 T cells at 8 dpi, obese mice also had less Treg cells at 8 dpi (Figure 4.6D). Additionally, 
we also assessed the level of Treg activation and found that obese mice had fewer CD103
+
 Tregs 
as well (Figure 4.6E). Given the discrepancy in Treg number in the lung airways, we also 
74 
 
measured Treg distribution in the lung (Figure 4.6F/6G) and mediastinal lymph nodes (Figure 
4.6H/I) of lean and obese mice during the course of the pH1N1 infection. We did not detect any 
differences in the percentage or number of Tregs or activated Tregs in these tissues. Due to the 
striking differences in the number of activated Tregs in the lung airways of HFD mice at 8 dpi, 
we also measured Treg distribution in LepR
H-/- 
and LepR
Hfl/fl
 mice at 8 dpi as well. Similarly, 
obese LepR
H-/-
 mice also had fewer Tregs and a lower number of activated Tregs in the lung 
airways at 8 dpi (Figure 4.6J/K).  
      
HFD-induced obese mice have elevated BALF leptin levels during pH1N1 infection 
Leptin regulates the function of a number of immune cells, and it is well-established that 
a deficiency of leptin signaling impairs immune defenses (2). However, obese mice have greater 
levels of circulating leptin, and it is currently unclear if and how this greater concentration of 
leptin may alter immune defenses. It has recently been shown that leptin monoclonal antibody 
treatment during pH1N1 infection limits mortality in obese mice (82). Therefore, we measured 
circulating leptin levels during pH1N1 infection in HFD and CD mice. As expected, serum leptin 
levels were elevated prior to infection and at 8 dpi in HFD mice compared with CD mice (Figure 
4.7A). Although leptin is elevated in circulation in obese mice, to our knowledge leptin levels in 
BALF during infection have not been measured. Of interest, obese mice had a greater 
concentration of leptin in the lung airways at 8 dpi infection compared with lean controls (Figure 
4.7B). Interestingly, BALF leptin did not differ between uninfected lean and obese mice. 
Therefore, the elevated BALF leptin is dependent on the infection. The source of BALF leptin is 
unclear, as it could be derived from circulating leptin leaking into the BALF due to damaged 
epithelial barriers. However, there was an increase in BALF total protein from 0 to 8 dpi in CD 
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fed mice (Figure 4.3E), but we did not detect an increase in BALF leptin in CD fed mice from 0 
to 8 dpi, suggesting that BALF leptin is not likely derived from impaired integrity of the lung 
epithelium. Additionally, serum leptin decreased in obese mice during the infection (likely due to 
reduced food intake). At this point the source of BALF leptin is unclear as other cell types in 
addition to adipocytes have been shown to secrete leptin, such as T cells (198). In summary, both 
serum and BALF leptin are elevated during a pH1N1 infection in diet-induced obese mice 
compared with lean, CD mice. 
 
Disruption of leptin signaling in T cells does not prevent pH1N1 mortality in diet-induced 
obese mice 
 
Leptin potentiates effector T cell responses and negatively regulates Treg proliferation 
(198). Therefore, perhaps excess leptin signaling is responsible for the reduced Treg number 
detected in the lung airways of obese mice. To investigate the impact of elevated leptin levels on 
T cell responses in obese mice during the context of influenza virus infection, we crossed leptin 
receptor floxed mice with LckCre mice, resulting in conditional disruption of leptin signaling in 
T cells. Weanling, male, littermate control LepR
Tfl/fl 
and LepR
T-/-
 mice were maintained on a 
HFD (60%) or CD for 15-17 wks. Figure 4.7C demonstrates that LepR
Tfl/fl 
and LepR
T-/- 
mice fed 
a HFD gained significantly more weight compared with CD mice, and there were no differences 
in weight gain between LepR
Tfl/fl 
and LepR
T-/- 
mice. Further, there were no differences in fasting 
glucose levels between obese LepR
Tfl/fl 
or obese LepR
T-/-
 mice. CD and HFD fed LepR
Tfl/fl 
and 
LepR
T-/-
 mice were infected with 5.8 x 10
2
 TCID50 pH1N1, and as expected HFD LepR
Tfl/fl 
mice 
were more susceptible to pH1N1 mortality compared with CD LepR
Tfl/fl 
mice (Figure 4.7E). 
Additionally, there were no differences in weight loss during the infection between dietary 
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groups or genotypes (Figure 4.7F). Therefore, leptin signaling in T cells does not likely mediate 
greater pH1N1 mortality observed in obese mice.  
 
Discussion 
In this study, we first demonstrated that both HFD fed obese and LFD fed lean mice are 
more susceptible to pH1N1 infection compared with lean CD mice. Currently, three studies have 
demonstrated that diet-induced obese mice are more susceptible to a primary pH1N1 infection 
(67,81,82). Two of these studies used a CD for the lean mouse group and a 45% or 60% kcal 
HFD for obese mice (67,82), and one study used a 60% kcal HFD compared with a nutrient 
matched, purified, 10% kcal low fat diet (81). In dietary studies, utilization of the proper control 
diet is critical for limiting introduction of confounding variables (69). Chow diets contain a 
variety of plant constituents that are not found in purified rodent diets, such as fiber and 
phytoestrogens (66,69). Dietary fiber and phytoestrogens can have profound metabolic and 
physiological effects, thereby complicating experimental results (66,69). Further, chow diets can 
have varying levels of ingredients from batch to batch, limiting experimental reproducibility. For 
these reasons, it is generally agreed that the most appropriate control for a high fat diet is a 
nutrient-matched, purified LFD differing only in carbohydrate and fat content (66,69). In this 
study, lean mice were fed either a CD or a LFD to compare to pH1N1 infection responses of 
obese mice. However, for the first time, we show that LFD fed mice are more susceptible than 
CD. This calls into question the most appropriate control diet for mouse models investigating the 
impact of obesity on immunity. Is the best control diet one that most closely matches the high fat 
diet, or one that results in the most “protective or effective” immune response? We propose that 
because CD mice were least susceptible to pH1N1 infection, they are the best control for 
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comparing infection responses to obese mice in this model. Further, although the LFD is 
matched in every aspect except for fat and carbohydrate content to the HFD, the fact that the 
levels of these two macronutrients are not identical may confound results. For example, perhaps 
elevated levels of sucrose in the LFD impact immune responses. It is unclear why LFD mice 
were more susceptible to pH1N1 infection compared with CD mice. LFD mice did have elevated 
levels of leptin compared with CD, so perhaps this contributed to greater mortality. Given these 
complications of utilizing a diet model of obesity, we also included a genetic model of obesity 
whereby the effects of diet could be eliminated. 
Ob/ob mice are a classic model of genetically-induced obesity in which lack of leptin 
satiety cues result in hyperphagia and obesity (65,223). O’brien et al. has previously 
demonstrated that ob/ob obese mice are more susceptible to pH1N1 mortality (67). Although this 
is informative and helps to address the complications of dietary models discussed above, a global 
deficiency of leptin signaling can cause physiologic complications that are not necessarily 
characteristic of obesity (65). Therefore, we utilized a genetic model of obesity in which leptin 
signaling is only disrupted in hypothalamic neurons. Although this model limits the introduction 
of confounding effects caused by a global disruption of leptin signaling, there is some evidence 
of Nkx2.1 expression in the lung, esophagus and during development (221).   
At this point, the two most well-defined mechanisms contributing to greater pH1N1 
severity in obese mice during a primary infection appear to be impaired lung wound healing (67) 
and hyperleptinemia (80). In addressing the consequences of hyperleptinemia on pH1N1 
outcomes in obese mice, we first set out to investigate if leptin was also elevated in the lung 
airways of obese mice. For the first time, we report that obese mice have greater leptin 
concentration in the lung airways during pH1N1 infection. The source of this greater BALF 
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leptin is unclear. It is unlikely that it is completely derived from serum leptin leaking into the 
lung for two reasons: 1) There is already leptin in the BALF prior to the infection. 2) BALF 
leptin decreases in lean mice during infection, despite greater lung airway damage (and without 
changes in circulating leptin level). Perhaps the elevated leptin in the BALF of obese mice is 
derived from infiltrating immune cells. 
 Leptin can enhance effector T cell inflammation and proliferation, and conversely is a 
potent inhibitor of Treg proliferation (198). Given that we detected greater lung damage in obese 
mice and fewer Tregs in the lung airways, we tested if disruption of leptin signaling in T cells 
ameliorates pH1N1 severity in obese mice. However, obese LepR
T-/-
 and LepR
Tfl/fl
 mice did not 
exhibit differences in pH1N1 susceptibility. The lack of differences in infection severity is likely 
explained by the fact that greater pH1N1 mortality in obese mice is driven by an array of factors 
and not simply leptin signaling in T cells. Although we did not detect differences in mortality 
between obese LepR
T-/-
 and LepR
Tfl/fl
 mice, further investigation of this model could be useful in 
eliminating plausible mechanisms. For example, if Treg number is enhanced in obese LepR
T-/- 
compared with obese LepR
Tfl/fl 
mice, this would indicate that the reduced Treg number is likely 
not responsible for the differences in mortality between lean and obese mice. We detected fewer 
Tregs in both diet and genetic models of obesity, and we hypothesize this is due to impaired 
proliferation due to excess leptin. Further, investigation of other infection parameters such as 
lung damage will reveal interesting information regarding the role of T cell leptin signaling in 
obesity-induced pH1N1 severity.  
We detected fewer BAL macrophages in the lung airways at 4 dpi in obese mice 
compared with CD mice, but there were no differences in neutrophils or NK cell number. This is 
surprising given that obesity enhances inflammatory macrophage polarization and the greater 
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lung damage observed in pH1N1 infected obese mice. However, we only assessed macrophage 
number by F4/80 staining. Utilization of other macrophage markers and macrophage subset 
(alveolar macrophage, M1, M2 etc.) markers would reveal information regarding the actual 
polarization/inflammatory status of these BAL macrophages in lean and obese mice. 
Obese mice had greater lung airway damage without major differences in lung infiltration 
or inflammation. Further, we did not detect differences in lung viral titers between lean and 
obese mice. It is unclear if the greater lung damage observed in obese mice is responsible for the 
enhanced mortality. Because we did not detect robust differences in lung inflammation or 
histopathology, this would suggest that greater damage to the lung epithelium may only be 
partially responsible for greater mortality in obese mice. Obesity also results in fatty liver and 
can impact heart and kidneys (224-226). Therefore, perhaps greater pH1N1 mortality is caused 
by synergistic effects of greater lung damage and other systemic consequences of obesity during 
influenza infection. 
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Tables and Figures 
 
Table 4.1 BALF cytokine concentrations during a primary pH1N1 infection 
 
Cytokine/Chemokine Diet Group Day 0 (pg/mL) Day 4 (pg/mL) Day 8 (pg/mL) 
IFNγ 
CD 1.5 ± 0.4 13.8 ± 4.7 130.1 ± 29.7 
LFD 1.9 ± 0.4 5.6 ± 0.8 96.7 ± 25.7 
HFD 1.6 ± 0.3 7.4 ± 0.9 478.6 ± 210.2 
KC 
 
CD 3.4 ± 0.6 200.0 ± 19.2 115.8 ± 17.1 
LFD 3.6 ± 1.0 216.2 ± 19.6 95.6 ±15.3 
HFD 3.0 ± 0.4 251.2 ± 15.3 237.7 ± 47.2*
#
 
IL-10 
CD 6.9 ± 1.6 4.0 ± 1.0 47.7 ± 12.7 
LFD 5.9 ± 1.1 4.0 ± 0.9 38.1 ± 6.4 
HFD 3.8 ± 1.1 4.1 ± 0.9 71.4 ± 25.2 
IL-17A 
CD 2.2 ± 0.4 2.7 ± 0.3 5.1 ± 0.8 
LFD 2.2 ± 0.4 1.5 ± 0.1 4.1 ± 0.9 
HFD 1.9 ± 0.2 2.1 ± 0.2 7.8 ± 1.9 
TNFα 
CD 380.0 ± 54.6 521.3 ± 21.5 422.1 ± 24.4 
LFD 469.2 ± 27.3 510.1 ± 9.5 248.9 ± 29.1^ 
HFD 438.2 ± 12.4 466.0 ± 21.7 435.3 ± 22.0
#
 
MCP-1 
CD 27.8 ± 7.5 2972.0 ± 579.6 4006.7 ± 1782.9 
LFD 24.9 ± 5.1 2559.6 ± 455.1 2682.5 ± 375.8 
HFD 14.3 ± 4.7 4588.9 ± 697.1
#
 8271.5 ± 2890.0 
RANTES 
CD 2.1 ± 0.5 103.2 ± 9.7 106.2 ± 20.9 
LFD 3.3 ± 0.6 89.6 ± 12.0 100.4 ± 15.8 
HFD 3.3 ± 0.3 81.5 ± 11.3 100.0 ± 12.8 
 
Table 4.1: Values represent mean concentration ± SEM (n=5-8), *p<0.05 HFD compared CD 
within same infection day, #p<0.05 HFD compared with LFD within same infection day, 
^p<0.05 LFD compared with CD within same infection day. IL-4 was below the limit of 
detection. 
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Figure 4.1 Diet-induced obesity results in greater pH1N1 infection mortality in mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: A, Weanling, male, C57BL6/J mice were randomly placed on a high fat (60% kcal 
fat), low fat (10% kcal fat) or chow diet for 14 wks (n>30). B, Mice were fasted overnight and 
blood glucose was measured (n=8). C-E, Non-fasted serum TAG (C), adiponectin (D) and leptin 
(E) were measured via ELISA (n=6-7). F, After 15 wks of dietary exposure, mice were infected 
intranasally with 5.8 x 10
2
 TCID50 pH1N1 and monitored for death (n≥21). G, Percent weight 
loss over the course of the pH1N1 (n≥21). H, Total weight loss during the infection (n≥21). I, 
After 14 wks of dietary exposure, mice were infected with 1.3 x 10
3
 TCID50 and death was 
monitored (n=12). J, Percent weight loss during the infection (n=12). K, Total weight loss during 
the infection (n=12). Each bar or data point represents mean   SEM. *p<0.05, **p<0.005, 
***p<0.0005. In Figure 1A, ***p<0.0005 comparing HFD with both LFD and CD mice, and 
#p<0.05 comparing CD and LFD mice. For Figures 1G, 1H, 1J, *p<0.05, **p<0.005, 
***p<0.0005 comparing HFD mice with CD and LFD mice. 
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Figure 4.2 Genetically obese mice are more susceptible to pH1N1 mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: A&B, Weight gain of male (A) and female (B) mice lacking leptin receptor 
signaling in hypothalamic neurons LepR
H-/-
, heterozygous mice Lep
H+/-
 and fully floxed 
LepR
Hfl/fl
 mice (n≥9). C&D, Mortality curves for male (C) and female (D) mice after infection 
with 5.8 x 10
2
 TCID50 pH1N1 at 13-17 wk of age (n≥9).  E&F, Percent weight loss for male (E) 
and female (F) mice after pH1N1 infection (n≥9). G&H, Total weight loss for male (G) and 
female (H) mice after pH1N1 infection (n≥9). Each bar or data point represents mean   SEM. 
*p<0.05, **p<0.005, ***p<0.0005. In Figures 1A-D, *p<0.05 or ***p<0.0005 comparing 
LepR
H-/-
 with both LepR
H-/-
 and LepR
H+/-
 mice.  For Figures 1 D-E, **p<0.05 or ***p<0.0005 
comparing LepR
H-/-
 with LepR
H-/-
 mice and 
#
p<0.05 or 
##
p<0.005 comparing LepR
H-/-
 with 
LepR
H+/-
 mice. For Figure F&G, *p<0.05, ***p<0.0005 comparing LepR
H-/-
 with both LepR
H-/-
 
and LepR
H+/-
 mice.  
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Figure 4.3 Obese mice exhibit greater lung damage during pH1N1 infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: A, BALF viral titers during pH1N1 infection, (n=4 for uninfected mice and n=7-8 at 
4 and 8 dpi). B, Total number of BAL cells (n≥8).C, Heat map demonstrating relative differences 
in fold increase of BALF cytokine concentration between CD, LFD and HFD mice determined 
from a multiplex assay (n=5-8). D, Total number of lung cells (n≥8). E, Fold increase of BALF 
protein during infection. Fold increase normalized to uninfected mice within each dietary group  
(n=6-10). F, Fold increase in BALF albumin. Fold increase normalized to uninfected mice within 
each dietary group (n=5-7). Each bar or data point represents mean   SEM. In Figure 4.3E&F, 
*p<0.05 comparing HFD with LFD and CD mice at 4 dpi. In Figure 4.3E, at 8 dpi *p<0.05 
comparing HFD with CD mice and 
#
p<0.05 comparing LFD and CD mice. 
84 
 
Figure 4.4 Obese mice did not exhibit differences in lung pathology during pH1N1 infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: H&E stained lung pathology slides from CD, LFD and HFD mice. The top panel of 
histology slides for each dpi is 10x magnification and the bottom panel is 40x magnification of 
the same slide. n=6-8. 
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Figure 4.5 Obese mice have fewer BAL macrophage during pH1N1 infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: A, Representative flow cytometry gating scheme comparing CD and HFD mice at 4 
dpi. Fluorescence minus one (FMO) staining controls were included for gating purposes. B, 
Percentage of F4/80
+
 cells of total CD3
-
 cells. C, Total number of CD3
-
F4/80
+
 cells (n=7-9). D, 
Percentage of Ly6G
+
 cells of total CD3
-
 cells. E, Total number of CD3
-
Ly6G
+
 cells (n=7-9). F, 
Percentage of NK1.1
+
 cells of total CD3
-
 cells. G, Total number of CD3
-
F4/80
+
 cells (n=7-9). 
Each bar or data point represents mean   SEM. *p<0.05, ***p<0.0005. 
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Figure 4.6 Diet- and genetic-induced obese mice have fewer BAL Tregs at 8 dpi 
 
Figure 4.6: A, Total number of BAL CD8
+
 T cells (n=3 at day 0 and n=7-9 at 4 and 8 dpi). B, 
Total number of BAL CD4
+
 T cells (n=3 at day 0 and n=7-9 at 4 and 8 dpi). *p<0.05. C, 
Representative flow cytometry gating scheme of BAL Tregs including mean percentage and 
standard error. *p<0.05 comparing HFD and CD mice at 4 dpi (n=3 at day 0 and n=7-9 at 4 and 
8 dpi). D&E, Total number of BAL Tregs (D) and activated Tregs (E) (n=3 at day 0 and n=7-9 at 
4 and 8 dpi). *p<0.05. F&G, Total number of mLN Tregs (F) and activated mLN Tregs (G) 
(n=8-10). H&I, Total number of Lung Tregs (H) and activated lung Tregs (I) (n=8-10). J&K, 
Total number of BAL Tregs (J) and activated BAL Tregs (K) from LepR
Hfl/fl
 and LepR
H-/-
 mice 
(n=4-5 at 0 dpi and n=7-8 at 8 dpi. **p<0.05. Each bar represents mean   SEM. 
  
8
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Figure 4.7 Leptin signaling in T cells does not mediate pH1N1 mortality in obese mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Serum leptin concentration in uninfected and at 8 dpi in CD and HFD mice (n=5-7). B, BALF leptin in uninfected and 8 
dpi infected CD and HFD mice (n=4-6). LepRT
fl/fl 
and LepR
T-/-
 littermate controls were randomly placed on a HFD (60% kcal fat) or 
CD (14.02% kcal fat) for 15 weeks and weight gain was measured weekly (n≥9). D, After 15-17 wks of dietary exposure, mice were 
infected with 5.8 x 10
2
 TCID50 pH1N1 and percent survival was measured (n≥10). E&F, Percent weight loss (E) and total weight lost 
(F) during the pH1N1 infection (n≥6). There were no differences in % original body weight between genotypes or dietary groups. 
There were no differences in total weight lost between genotypes within each dietary group. Each bar represents mean   SEM. 
*p<0.05, ***p<0.0005.   
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CHAPTER V: H NMR-BASED PROFILING REVEALS DIFFERENTIAL  
IMMUNE-METABOLIC NETWORKS DURING INFLUENZA  
VIRUS INFECTION IN OBESE MICE
2
 
 
Introduction 
Obesity has reached epidemic proportions (8). Global approximations report that two out 
of every three individuals are clinically overweight (BMI≥25-29.9) or obese (BMI≥30) (3). The 
pathological complications of obesity are diverse and include co-morbidities such as 
cardiovascular disease, type 2 diabetes, and hypertension, to name a few (1,227). Obese 
individuals are also more susceptible to viral and bacterial infections (2). In 2009, the Centers for 
Disease Control and Prevention reported a high prevalence of obesity among intensive care 
patients with confirmed 2009 pandemic H1N1 influenza (pH1N1) infection (4). Several 
investigations have since established obesity as an independent risk factor for enhanced pH1N1 
(4-7,228) and seasonal influenza infection severity (17,229,230). Given that seasonal influenza 
epidemics result in 250,000 to 500,000 deaths globally (9) and future pandemics are likely 
imminent (10), understanding how obesity enhances influenza severity is a global public health 
concern.     
We have previously shown that obese individuals exhibit impaired cellular and humoral 
immune responses to influenza vaccination (12). Further, mouse models of obesity have 
extensively demonstrated that obesity enhances influenza infection mortality 
                                                          
2
This chapter was published in PLoS One:  
Milner J.J., Wang J., Sheridan P.A., Ebbels T., Beck M.A.*, Saric, J.* 2014. 
1
H NMR-based 
profiling reveals differential immune-metabolic networks during influenza infection in obese 
mice. PLoS One. In Press. *Co-last authors 
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(14,67,68,78,79,81,82). Both innate and adaptive influenza immune defenses are altered by 
obesity, but elucidation of the underlying mechanisms driving greater influenza severity in obese 
mice is currently lacking (2,14,78,79,231). Further, obesity is inherently a metabolic disease, and 
thus far, no studies have considered how dynamic changes in metabolism during influenza may 
impact immunity and infection outcome in the obese.    
Metabolic profiling, combining 
1
H nuclear magnetic resonance (NMR) spectroscopy and 
multivariate statistical data analysis, has found wide application in metabolic syndrome related 
diseases and has also gained significant momentum in infectious diseases for discovery of 
predictive and diagnostic biomarkers (232-236). In more recent years, the approach has evolved 
towards a more systemic assessment of host response, and integrating immune measures has 
become established in particular (237,238). The purpose of this study was to develop a global 
view of the impact of obesity on metabolism and immunity during influenza infection and to 
generate data which can serve as the basis for the formation of new mechanistic hypotheses and 
perhaps new prognostic or diagnostic methodology.   
In the present study, lean and obese mice were infected with a mild dose of influenza 
A/PR/8/34 (H1N1) and subsequently tissues and biofluids were harvested for metabolic 
profiling.
 1
H NMR-based profiling revealed distinct metabolic signatures between infected lean 
and obese mice. Interestingly, we identified unique metabolic signatures in urine and fecal 
samples that allowed for discrimination of infection status and distinguished uninfected and 
infected lean and obese mice. Further, the metabolic analysis was extended to include lung 
tissue, bronchoalveolar lavage fluid (BALF), serum, mesenteric white adipose tissue (WAT), and 
liver from infected lean and obese mice. We detected significant alterations in ketone body, lipid, 
choline, nucleotide, vitamin, amino acid and carbohydrate metabolic pathways in influenza 
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infected obese mice. We also analyzed T cell populations from lean and obese infected mice to 
identify immune-metabolic correlation structures, and several interactions between a variety of 
metabolites and BAL and draining lymph node T cell populations were uncovered. Identification 
of differential metabolic signatures and immune-metabolic structures in lean and obese mice 
facilitates the establishment of metabolic profiling as a useful tool for characterizing influenza 
infection responses and advances the current understanding of potential factors contributing to 
impaired influenza protection in obese mice.   
 
Materials and methods 
 
Ethics Statement 
 Animal experiments were conducted at the University of North Carolina at Chapel Hill 
Animal Facility, which is fully accredited by the American Association for Accreditation of 
Laboratory Animal Care. All mouse-related procedures were approved by the University of 
North Carolina at Chapel Hill Institutional Animal Care and Use Committee.  
 
Animal housing and maintenance  
 Weanling, male, C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed 
under pathogen free conditions and fed a high fat (45% kcal fat, Research Diets D12451) or low 
fat, control diet (10% kcal fat, Research Diets D12450B, New Brunswick, NJ) for 20 weeks.  
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Reagents  
 Phosphate buffer for 
1
H NMR acquisition of urine and extracts was made at a D2O:H2O 
ratio of 1:1 at a pH of 7.4 containing Na2HPO4 and NaH2PO4 (Sigma-Aldrich). D2O served as a 
field frequency lock and sodium 3- (trimethylsilyl) [2,2,3,3-2H4] propionate (Sigma-Aldrich) at 
0.01% was added as a chemical shift reference represented at δ 0.0. For 1H NMR acquisition of 
serum 0.9% saline was equally made up in 50% D2O (Sigma-Aldrich). HPLC-grade water, 
chloroform, and methanol, for tissue extractions were obtained from VWR International Ltd.  
 
Influenza infection and sample collection 
 Influenza A/Puerto Rico/8/1934 (H1N1, PR/8), (ATCC, Manassas, VA), was propagated 
in embryonated chicken eggs as described previously (14,78). For influenza inoculations, mice 
were lightly anesthetized via isoflurane inhalation, and infected with 1.1x10
2
 50% tissue culture 
infective dose (TCID50) PR/8 in 50 µL of phosphate buffered saline via non-invasive 
oropharyngeal aspiration, as similarly reported (14,193,194).    
 Urine and fecal samples for metabolic profiling were obtained at three different time 
points: one day prior to infection (D-1), 2 and 6 dpi (Figure 1). Details regarding fecal/urine 
sample collection are described elsewhere (234). At 9 dpi, liver, lungs, mesenteric (visceral) 
white adipose tissue (WAT), bronchoalveolar lavage fluid (BALF) and mediastinal lymph nodes 
(mLN) were harvested and further processed for flow cytometry or were flash frozen in liquid 
nitrogen. Collection of BALF was performed as previously described (14,78). Urine, serum, 
fecal pellets, BALF, liver, lung and WAT samples were shipped to Imperial College London on 
dry ice for 
1
H NMR data acquisition and analysis.  
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Flow cytometry 
BAL and mLN cells were processed and stained for flow cytometry as previously 
described (14,78) with the following antibodies: CD16/32 (Fc blocker),  CD4 (FITC), CD25 
(PE-Cy7), and Foxp3 (APC) from eBioscience (San Diego, CA); CD3 (APC/Cy7) and CD8 
(PerCP) from BioLegend (San Diego, CA). The MHC class I tetramer (PE) specific for H-2Db-
resricted epitope of the influenza nucleoprotein (NP, DbNP366-74) of PR/8 was obtained from the 
NIH Tetramer Core Facility (Atlanta, GA). Stained cells were subsequently analyzed on a CyAn 
ADP Analyzer flow cytometer (Beckman Coulter, Inc., Fullerton, CA), and all flow cytometry 
data were analyzed via FlowJo Software (TreeStar, Ashland, OR). All flow cytometry analysis of 
T cells consisted of a doublet exclusion gate followed by gating of CD3
+
 cells for further 
analysis of CD4
+
 and CD8
+
 T cell populations. 
 
Sample preparation and acquisition of 
1
H NMR spectral data 
 Urine, feces, serum, and tissue samples were prepared according to previously published 
protocols (234,239). Individual BALF samples (200 μl) were mixed with phosphate buffer (400 
μl) and 550 μl of the mixture was subsequently transferred into 5 mm diameter standard NMR 
tubes for data acquisition (Bruker Biospin, Rheinstetten). All biological samples were analyzed 
using a 600 MHz Avance DRX NMR spectrometer (Bruker; Rheinstetten), employing a standard 
one dimensional (1D) 
1
H NMR Noesypr1d pulse sequence with water suppression (recycle delay 
(rd)-90°-t1-90°-tm-90°-acquisition time) for all samples. Recycle delay (rd) and mixing time 
(tm) were set to 2 s and 100 ms respectively. For obtaining more comprehensive information on 
the serum samples, two additional pulse programs were utilized namely Carr-Purcell-Meiboom-
Gill (cpmgpr) and diffusion edited spectroscopy (ledbipolpr) (239). The numbers of scans were 
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adjusted for each biological matrix, whereby urine and serum were analyzed in 256 and extracts 
in 128 scans to obtain maximum signal output. Data from each sample was accumulated into 32 
k data points within a spectral width of 20 ppm. 
 
Pre-processing of spectral data  
 Topspin 3.1 (Bruker Biospin) was utilized for partially pre-processing of the raw spectra, 
including manual phasing, baseline correction and calibration of the chemical shifts to the TSP 
signal at δ 0.00 or to the lactate doublet at 1.33 representing the CH3 signal, for serum samples. 
Spectra were subsequently imported into a MATLAB interface (Mathworks Inc., USA) where 
regions containing ethanol, methanol, urea, and water resonances were cut out from the whole 
spectra. Selected regions were δ 1.049-1.232, δ 3.599-3.7 (ethanol) for BALF spectra, δ 4.704-
6.318 (H2O and urea) for urine, δ 3.332-3.443 (methanol), δ 4.598-5.001 (H2O) for serum, δ 
4.216-5.556 (H2O) for feces, δ 4.723-5.012 (H2O) for liver, δ 4.713-5.075 (H2O) for lung, and δ 
4.675-5.093 (H2O) for WAT. All remaining spectral regions were aligned and normalized to the 
median spectrum according to an in-house developed MATLAB script (Dr. Kirill Veselkov) 
(240).  
 
Multi- and uni-variate data treatment  
 Processed spectral data were exported to SIMCA-P software (Umetrics, Sweden) for 
Principal component analysis (PCA) and projection to latent structure discriminant analysis 
(PLS-DA) for obtaining an overview on the data distribution and presence of class differences 
(241,242). For identification of the discriminatory metabolites, orthogonal PLS-DA (O-PLS-DA) 
was applied using an in-house developed script in MATLAB including a 7-fold cross validation 
94 
 
(243). Metabolites that are related to a certain class are represented by yellow to red colors in the 
color code included in the O-PLS-DA plots, whereby the exact correlation value can be extracted 
from the main plot in MATLAB. Here, only candidate biomarkers above a correlation threshold 
corresponding to p ≤ 0.05 were selected as significant.  
 In order to explore correlation structures between metabolic data and T cell populations, 
an additional correlation analysis was conducted. The spectral information which built the X-
matrix was therefore integrated with a second Y-matrix that contained the flow cytometry data. 
The Pearson-based correlation script further contained a peak picking algorithm to reduce 
inclusion of noise, and a 10,000 fold permutation resulting in display of correlations with p ≤ 
0.05 only. Identity of peaks was confirmed by using in-house NMR chemical shift database, 
Chenomx NMR suite profiler software (Chenomx Inc, USA), and published 
1
H NMR 
assignments (234,244,245). Identities were further confirmed by using statistical total correlation 
spectroscopy (STOCSY) in a MATLAB environment (243).  
 
Results 
 
Metabolic profiling uncovers distinct metabolic perturbations in influenza infected obese 
mice 
 
Weanling, male C57BL/6J mice were maintained on a high fat (45% kcal fat) or a low 
fat, control diet (10% kcal fat) for 20 weeks. Following the dietary exposure, obese mice 
weighed 33% more than lean mice (Figure 5.1A). Figure 5.1B is a representative timeline for 
collection of samples processed for immune-metabolic characterization, and all samples were 
obtained from the same cohort of lean and obese mice.  Following the 20 wk dietary exposure, 
mice were infected with 1.1x10
2
 TCID50 of PR/8. Although obese mice lost more absolute 
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weight compared with lean mice (Figure 5.1C), there were no differences detected in percent 
weight loss between the two groups (Figure 5.1D). It is well established that obese mice are more 
likely to die from influenza if given a sufficient viral dose (67,68,78,79,81).  However, we 
utilized a relatively mild infection dose, as only 10% of lean and obese mice succumbed to the 
infection. We chose a mild infection for this model in order ensure that we captured metabolic 
changes induced by obesity during infection rather than secondary responses caused by lethal 
infection conditions.  
We first set out to determine if metabolic profiling could distinguish urine and fecal 
samples from uninfected and infected lean and obese mice. We chose urine and feces because 
these are biosamples that could easily be tested in humans. Further, we chose to sample urine and 
feces at 2 dpi and 6 dpi to capture metabolic changes during early and late infection responses. 
Figure 5.2 represents a PCA scores plot showing clear separation of naïve (D-1) urine samples 
from early infection (D2) and later infection (D6) time points for lean (Figure 5.2A) and obese 
mice (Figure. 5.2B). Pre-infection and 6 dpi samples were furthermore combined in a PLS-DA 
analysis in order to capture whether obesity status or infection state was the predominant 
influence to the murine metabolic profile (Figure 5.2C). Of interest, all infection-dietary groups 
displayed metabolically distinct urinary profiles.   
Analysis of urinary and fecal metabolites differentially altered in lean and obese mice 
during the infection revealed mixed effects in a variety of metabolic processes, including 
perturbations in nucleotide, vitamin, ketone body, amino acid, carbohydrate, choline and lipid 
metabolism (Table 5.1). Reflective of impaired glucose tolerance, characteristic of obesity, obese 
mice had greater urinary glucose levels prior to infection and throughout the course of the 
infection (246,247). Further, uninfected obese mice had significantly higher concentrations of 
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urinary taurine, ureidopropanoate, 1-methylnicotinamide, several unknown metabolites and 
lower levels of trimethylamine. At 2 dpi ascorbate, ureidopropanoate and acetylcarnitine were 
detected in the urine of obese mice, whereas trimethylamine levels were greater in lean mice at -
1 and 2 dpi. Urinary 3-hydroxybutyrate concentration was greater at 6 dpi in obese mice as well 
as several lipid metabolites in fecal extracts at 2 dpi.  
The metabolic analysis was also extended to include assessments of BALF, lung tissue, 
serum, liver and mesenteric WAT from lean and obese mice at 9 dpi (Table 5.2). To limit 
variation within dietary groups, due to intra-individual differences between mice, all samples 
used for profiling were obtained from the same cohort of mice. Although this is an inherent 
strength in our model, it limited the analysis to one time period for harvesting terminal samples 
(serum, WAT, BALF, lung and livers). We specifically chose BALF and lung to examine local 
changes at the site of infection, and we included peripheral tissues and serum to enhance 
understanding of the systemic and global consequences of obesity during influenza. Analyses of 
tissues at 9 dpi revealed that WAT showed the greatest number of altered metabolites, whereby 
the majority of changes were linked to amino acid metabolism (Table 5.2). Additionally, serum 
showed a high degree of metabolic change between lean and obese mice, including relatively 
higher general lipid levels in the obese mice (Figure 5.6, Table 5.2). However, lean mice had 
greater levels of serum acetone, 3-hydroxybutryate and acetate. Lung and BALF did not show 
any significant differences between lean and obese mice at 9 dpi.   
   
Differential immune-metabolic correlations in influenza infected lean and obese mice 
Metabolic profiling has previously been used to explore immune regulatory systems 
during infections by applying multivariate statistical methods to uncover metabolic-immune 
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interactions (238,248). To further assess the co-variation between tissue/biofluid metabolites and 
immune parameters in our model, a correlation analysis was conducted between T cell 
population numbers and 
1
H NMR data for lean and obese statuses separately in order to 
characterize the systemic background metabolism linked to T cell responses. Although a variety 
of cellular defenses are altered by obesity, we chose to focus our analysis on T cell populations 
because this cell type is consistently altered by obesity during influenza infection 
(14,67,78,213,231). We have previously detected perturbations in antigen specific CD8
+
 T cell 
and regulatory T cell (Tregs) responses during influenza infection in obese mice (14,78,79,213); 
therefore, we focused our immune-metabolic integration on these cell types in particular. For 
influenza-specific CD8
+
 T cells, we utilized an MHC class I tetramer specific for H-2Db-
resricted epitope of the influenza nucleoprotein (NP, DbNP366-74) of PR/8, and Tregs were 
identified as CD4
+
Foxp3
+
CD25
+
 cells. 
The 
1
H NMR data from each biological compartment (i.e. lung, liver, WAT, feces, 
BALF, serum, and urine) were correlated with BAL and mLN T cell populations at 9 dpi. Urine 
(6 dpi), lung (Tables 5.3 and 5.4) and liver presented the highest amount of T cell-metabolite 
correlations in both lean and obese mice. Interestingly the correlations were not restricted to the 
corresponding cellular compartment but showed systemic links. For example, 3-hydroxybutyrate 
in serum negatively correlated with BAL CD4
+
 T cells in lean mice, whereas urinary 3-
hydroxybutyrate positively correlated with BAL CD4
+
 T cells in obese mice (Table 5.5). A 
relatively similar pattern of correlations was detected for BAL Tregs (CD4
+
CD25
+
Foxp3
+
), but 
3-hydroxybutyrate in the lungs of obese mice positively correlated with BAL Tregs (Table 5.3, 
Figure 5.4). Further, 3-hydroxybutrate in several compartments correlated with various mLN and 
BAL CD8
+
 T cell populations in lean and obese mice. Other metabolites, such as choline, taurine 
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and creatine from a variety of tissues/biofluids were found to be significantly associated with 
several T cell populations in the lung airways and mLN. A detailed list of correlative metabolic 
markers is provided in Tables 5.3/4 and Supplementary Table 5.1. Significant correlations 
among metabolites and T cell populations may result from co-variation without indication of a 
mechanistic link, but it is also possible that detected correlations reveal underlying mechanisms 
directly or indirectly affecting T cell distribution and function in lean and obese mice. 
  
Discussion 
Globally, 500 million adults are clinically obese, and the number of pathophysiological 
complications and identified health risks of excess adiposity continue to mount (3). Although a 
number of innate and adaptive immune defenses are altered by obesity during influenza 
infection, explanatory mechanisms remain relatively undefined. Through metabolic assessment 
of urine and feces, we demonstrated that metabolic profiling can successfully distinguish 
uninfected lean and obese mice, naïve and infected mice, and lean and obese mice infected with 
influenza. Metabolic analysis of serum, WAT and livers also revealed differences in a variety of 
metabolic pathways in obese mice during the peak of influenza immune responses. Lastly, 
statistical relationships between T cell responses and tissue/biofluid metabolites were uncovered 
allowing for a thorough differential immune-metabolic characterization.  
 Metabolic profiling of urine and feces revealed greater levels of urinary taurine, 
ureidopropanoate, 1-methylnicotinamide, glucose and fecal choline in uninfected obese mice. 
Metabolic changes detected in the urine and feces may reflect local changes in the kidneys or 
gastrointestinal system, as well as systemic alterations in metabolism. To our knowledge, there 
are currently no reports defining how influenza infection alters metabolite profiles in the urine 
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and feces of mice. During infection, acetylcarnitine, ascorbate, glucose and 3-hydroxybutyrate 
were elevated in the urine of obese mice. Of interest, a variety of lipid metabolites and 
propionate (a short chain fatty acid) (249) were detected at greater concentrations in the feces of 
obese mice at 2 dpi. Because these changes were not observed prior to infection, the increased 
levels of these metabolites are specific to the infection in obese mice (and not simply due to diet 
or obesity status). This finding may yield new hypotheses related to obesity and influenza 
infection, such as: Are there local changes in the gastrointestinal system of obese mice during 
influenza that may impact infection outcome? Does obesity induce alterations in the gut 
microbiota during influenza, potentially impacting infection responses (propionate can be 
produced by gut microbiota) (249)? Further, acetylcarnitine was detected at higher levels in the 
urine of obese mice at 6 dpi. Acetylcarnitine is the acetylated form of carnitine, which is utilized 
in fatty acid transport into mitochondria for subsequent β-oxidation. Therefore, various 
metabolites related to lipid metabolism were significantly altered in the feces and urine of obese 
mice, perhaps suggesting alterations in lipid metabolism contributes to differential infection 
responses in obese mice. 
 Ascorbate (vitamin C) was significantly higher in the urine of obese mice at 2 dpi. Excess 
levels of ascorbate in mice are controlled, in part, through urinary excretion (250,251). Unlike 
humans, mice have the ability to synthesize endogenous ascorbate (252,253). Further, during 
times of stress, mammals upregulate ascorbate biosynthesis (254). Ascorbate fulfills a variety of 
physiological functions, including regulation of oxidative stress (253,255). Elevated ascorbate in 
the urine may be indicative of greater levels of oxidative stress in infected obese mice. Oxidative 
stress and vitamin C deficiency in mice can increase influenza infection pathology and mortality 
(178,253,256). Further, influenza infection and obesity are independently associated with greater 
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levels of oxidative stress (177,257). Therefore, it is likely that obesity exacerbates oxidative 
stress conditions during influenza infections, ultimately affecting infection outcome. Further, if 
vitamin C requirements are increased during infection in the obese, perhaps obese humans 
require greater ascorbate intake during influenza infection and should supplement during 
influenza seasons. It is interesting that ascorbate was detected at greater levels in the urine of 
obese mice, but it is unclear why elevated levels weren’t detected in the serum or the liver 
(primary site of synthesis). Perhaps, at 9 dpi, when serum and livers were harvested, ascorbate in 
obese mice returned to similar levels as in lean mice.  
 Another interesting finding revealed by metabolic profiling was that glucose was 
significantly elevated in the urine of obese mice prior to infection, and at 2 and 6 dpi. Glucose 
intolerance often results in glucosuria (246,258). Further, obese mice had greater levels of 
glucose in the serum and liver at 9 dpi compared with lean mice. It has been extensively 
demonstrated that diet-induced and genetic obese mice exhibit elevated blood glucose levels 
(65,242). However, tissue and circulating glucose levels in obese mice have never been 
measured during the context of an influenza infection. Chronically elevated glucose can have a 
variety of pathological effects, including glycation products, oxidants, hyperosmolarity and 
perturbations in cell signaling pathways (259). Therefore, it would be interesting to investigate 
influenza severity in a model in which obese mice have normalized insulin sensitivity and 
glucose tolerance (235). 
In recent years, an abundance of research has focused on how metabolism is a critical 
regulator of immune cell function (260). Manipulation of nutrient availability in culture or 
genetic manipulation of genes that regulate metabolic pathways can have a profound impact on 
immune activity and disease outcome (1,260). However, it is relatively unclear how metabolites 
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and nutrients in the immune cell microenvironment may alter cellular metabolism, distribution 
and function during the context of an infection. Therefore, we took advantage of this 
comprehensive metabolic analysis and assessed significant interactions between T cell 
populations and metabolites. A number of immune-metabolic correlations were uncovered. For 
example, lung choline and phosphocholine were positively associated with BAL Tregs and other 
CD4
+
 T cell populations in lean mice but not in obese mice. Perhaps, perturbations in 
choline/phosphocholine metabolism may impact T cell responses in obese mice. These findings 
could be indicative of direct or indirect T cell-metabolite interactions, although it is also possible 
that these associations are biologically insignificant. Nonetheless, identification of BAL and 
mLN T cell-metabolite correlates provides a more dynamic and global assessment of the 
consequences of obesity during influenza infection. 
The urinary and fecal data are particularly interesting given the non-invasive nature of 
these bio-samples and the high degree of separation detected between naïve and infected, lean 
and obese mice. Numerous reports have established metabolic profiling of urine can identify 
biomarkers and metabolic matrices that can distinguish disease states, with the capability of 
ultimately guiding treatment (80,261,262). At 2 dpi, prior to significant weight loss and any 
obvious signs of sickness, we identified a unique metabolic fingerprint in the urine and feces of 
influenza infected obese mice, consisting of perturbations in lipid, nucleotide, carbohydrate, 
microbial, and vitamin metabolism. Given the rapidity of influenza transmission during 
epidemics and pandemics and the sudden onset of severe symptoms in infected individuals (9), 
identification of a metabolic profile unique to an early infection time point holds widespread 
implications for personal and public health. We have identified a metabolic signature that could 
be used to predict influenza infection status even prior to any obvious signs of illness. Further 
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testing can determine if this signature is unique to influenza infection rather than a generalized 
response to an infection or inflammation.  
Taken together, this investigation establishes metabolic profiling as a useful tool for 
characterizing infection responses during influenza and identifying potential pathways and 
mechanisms contributing to altered immunity in obese mice. Teasing apart differential responses 
during influenza infection is key to understanding the mechanisms driving greater disease 
severity in obese mice compared with lean mice. Further utilization of metabolic profiling as a 
complimentary tool to immunological measures of infection outcome could help advance the 
current knowledge of the response to influenza infection in other rodent research models and 
may have potential applications in clinical and research settings. 
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Tables and Figures 
 
Table 5.1. Metabolic biomarkers recovered from urine and fecal extracts during influenza 
infection in lean and obese mice  
 Metabolic Pathway Metabolite Day -1 Day 2 Day 
6 
Ketone Body Metabolism 3 hydroxybutyrate 
  
Urine 
Lipid Metabolism acetylcarnitine 
 
Urine 
 
 
(CH2)n 
 
Feces 
 
 
CH2CH2CO 
 
Feces 
 
 
CH2CH2CO 
 
Feces 
 
 
propionate 
 
Feces 
 
 
taurine Urine 
  
Choline Metabolism choline Feces 
  
Microbial Metabolism trimethylamine Urine Urine 
 
Nucleotide Metabolism ureidopropanoate Urine Urine 
 
Vitamin Metabolism ascorbate 
 
Urine 
 
 
1-methylnicotinamide Urine 
  
Carbohydrate Metabolism glucose Urine Urine Urine 
UK1 2.458(s) 
 
Feces 
 
UK2 8.54(d), 8.33(d), 6.7(d), 6.67(d), 
3.65(s) 
Urine Urine Urine 
 
Table 5.1: Bolded and underlined urine and feces indicates that metabolite was significantly 
higher in obese mice, and metabolites in normal font were significantly lower in obese mice. UK: 
unknown metabolite. n=8-9. 
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Table 5.2 Discriminatory metabolites between lean and obese mice at 9 days post-infection 
in liver, serum and white adipose tissue samples 
 
Metabolic Pathway Metabolite Liver Serum WAT 
Amino acid Metabolism alanine 
  
+ 
 
glutamate 
  
+ 
 
isoleucine 
  
+ 
 
leucine 
  
+ 
 
lysine 
  
+ 
 
methionine 
  
+ 
 
phenylacetylglycine 
  
+ 
 
tyrosine 
  
+ 
 
valine 
  
+ 
Biosynthesis of Secondary 
Metabolism 
scyllo-inositol 
  
- 
Carbohydrate Metabolism glucose + + 
 
Ketone Body Metabolism acetone 
 
- 
 
 
3 hydroxybutyrate 
 
- 
 
Lipid Metabolism glycerophosphocholine 
 
+ 
 
 
LDL (=CH-CH2-) 
 
+ 
 
 
LDL (-CH=CH-CH2-
CH=CH-)  
+ 
 
 
LDL (CH3) 
 
+ 
 
Pyruvate Metabolism acetate 
 
- 
 
 
Table 5.2:
 
Metabolites that were detected at a significantly greater level in obese mice are 
indicated by +, whereas – represents metabolites detected at lower levels in obese mice 
compared with lean mice,  n=8-9. 
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Table 5.3 Lung metabolite correlation patterns with BAL T cell populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3: Underlined metabolites represent a significant negative correlation, and text without an underline indicates a significant 
positive association. Correlation analysis is based on a Pearson correlation matrix validated by 10,000 permutations. n=8-9. 
BAL Cells Lean Obese 
Total BAL cell number creatine, glycerol, taurine 
 
CD4+ T cells creatine, glycerol, phosphocholine, taurine 
 
CD4+CD25+ T cells 
3-hydroxybutyrate, acetate, alanine, creatine, glycerol, 
lactate, phosphocholine, taurine  
CD4+CD25+FoxP3- T cells 
3-hydroxybutyrate, creatine, glycerol, lactate, 
phosphocholine, taurine 
 
CD4+CD25+Foxp3+ T cells 
3-hydroxybutyrate, acetate, choline, creatine, glycerol, 
lactate, phosphocholine, taurine 
3-hydroxybutyrate 
CD4+FoxP3+ T cells 
3-hydroxybutyrate, acetate, choline, creatine, glycerol, 
lactate, phosphocholine, taurine 3-hydroxybutyrate 
CD4+FoxP3hi T cells 
3-hydroxybutyrate, acetate, choline, creatine, glycerol, 
lactate, phosphocholine, taurine  
CD8+CD25+ T cells 3-hydroxybutyrate, creatine  
CD8+DbNP366-74
+ T cells 
 
choline, glycerol 
CD8+CD25+DbNP366-74
+ T cells  
acetate, alanine, choline, creatine, glucose, glycerol, 
lactate, leucine, methionine, phosphocholine, taurine, 
valine 
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Table 5.4 Lung metabolite correlation patterns with mLN T cell populations 
 
Table 5.4: Underlined text represents a significant negative correlation, and text without an underline indicates a significant positive 
association. Correlation analysis is based on a Pearson correlation matrix validated by 10,000 permutations. n=8-9.
mLN Cells Lean Obese 
Total mLN cell number 
 
glucose 
CD4+ T cells 
 
glucose, glycerol 
CD4+CD25+Foxp3+ T cells alanine, leucine, valine glucose 
CD4+Foxp3+ T cells leucine, valine 
 
CD4+Foxp3hi T cells  glucose 
CD8+ T cells  3-hydroxybutyrate, glucose, glycerol 
CD8+DbNP366-74
+ T cells 
 
3-hydroxybutyrate, acetate, alanine, choline, 
creatine, glucose, glycerol,  lactate, leucine, 
methionine, phosphocholine, valine 
CD8+CD25+DbNP366-74
+ T cells 
 
3-hydroxybutyrate, acetate, alanine, choline, 
creatine, glucose, glycerol, lactate, leucine, 
methionine, taurine, valine phosphocholine 
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Table 5.5 Correlation patterns between 
1
H NMR data and BAL or mLN T cell populations 
Liver NMR 
 
Lean Obese 
BAL cells Total BAL cell number glucose, leucine 
 
 CD4
+
 T cells 
acetate, alanine, glucose, lactate, 
leucine 
acetate, glucose, 
glutamine, isoleucine 
 
CD4
+
CD25
+
 T cells 
acetate, alanine, glucose, glycerol, 
lactate, leucine  
 
CD4
+
CD25
+
FoxP3
-
 T cells 
acetate, alanine, choline, glucose, 
glycerol, lactate, leucine  
 
CD4
+
FoxP3
+
 T cells glucose 
 
 
CD4
+
FoxP3
hi
 T cells glucose 
 
 CD4
+
CD25
+
Foxp3
+
 T cells glucose  
 CD8
+
CD25
+
 T cells glucose 
acetate, choline, glucose, 
glutamine, isoleucine, 
lactate 
 
CD8
+
CD25
+
DbNP366-74
+
 T cells 
 
alanine, aspartate, choline, 
glucose, glutamate, 
glycerol 
  
1
0
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mLN cells CD4
+
 T cells choline  
 
CD4
+
CD25
+
 T cells acetate, choline 
 
 
CD4
+
CD25
+
Foxp3
+
 T cells acetate, choline 
 
 
CD4
+
Foxp3
+
 T cells choline 
 
 
CD4
+
Foxp3
hi
 T cells choline 
 
 
CD4
+
CD25
+
Foxp3
-
 T cells acetate, choline 
 
 
CD3
+
CD8
+
 T cells choline 
 
 
CD8+DbNP366-74
+ T cells 
 
choline, glucose 
 
CD8+CD25+DbNP366-74
+ T cells 
 
choline, glucose, glutamate 
WAT NMR 
 
Lean Obese 
BAL cells CD4
+
 T cells 
 
choline, lactate, 
phosphocholine, taurine 
  
1
0
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 CD4
+
Foxp3
+
 T cells  phosphocholine 
 
CD4
+
FoxP3
hi
 T cells 
 
choline, phosphocholine, 
taurine 
 
CD8
+
CD25
+
 T cells 
 
alanine, glycerol, leucine 
mLN cells Total mLN cells taurine 
 
 CD3
+
CD4
+
 T cells glycerol, lactate, taurine  
 
CD4
+
CD25
+
Foxp3
-
 T cells 
 
leucine 
 CD3
+
CD8
+
 T cells glycerol, lactate, taurine  
Feces NMR 
 
Lean Obese 
BAL cells Total BAL cell number 
 
deoxycholic acid 
 
CD4
+
CD25
+
 T cells 
 
deoxycholic acid 
 
CD4
+
CD25
+
FoxP3
-
 T cells 
 
deoxycholic acid 
  
1
1
0
 
 
CD4
+
CD25
+
Foxp3
+
 T cells 
 
deoxycholic acid 
 
CD4
+
FoxP3
+
 T cells 
 
deoxycholic acid 
 
CD4
+
FoxP3
hi 
T cells 
 
 deoxycholic acid 
 CD8
+
CD25
+
 T cells  deoxycholic acid 
 CD8
+
CD25
+
DbNP366-74
+
 T cells acetate  
 
CD8
+
DbNP366-74
+
 T cells acetate 
 
mLN cells CD3
+
CD4
+
 T cells deoxycholic acid 
 
 
CD4
+
CD25
+
Foxp3
-
 T cells 
 
deoxycholic acid 
 
CD3
+
CD8
+
 T cells deoxycholic acid deoxycholic acid 
BALF NMR 
 
Lean Obese 
  
1
1
1
 
mLN cells CD8+DbNP366-74
+ T cells lactate 
 
 
CD8+CD25+DbNP366-74
+ T cells lactate 
 
Serum NMR 
 
Lean Obese 
BAL cells CD3
+
CD4
+
 T cells 3-hydroxybutyrate, acetone 
 
 
CD4
+
CD25
+
 T cells 3-hydroxybutyrate, acetone 
 
 
CD4
+
CD25
+
Foxp3
+
 T cells 
 
3-hydroxybutyrate 
 
CD4
+
CD25
+
FoxP3
-
 T cells 3-hydroxybutyrate, acetone 
 
 
CD4
+
FoxP3
+
 T cells 
 
3-hydroxybutyrate 
 
CD4
+
FoxP3
hi
 T cells 
 
3-hydroxybutyrate 
 
CD3
+
CD8
+
 T cells 3-hydroxybutyrate, acetone 
 
  
1
1
2
 
 
CD8
+
CD25
+
 T cells 3-hydroxybutyrate, acetone 
 
mLN cells CD4
+
CD25
+
Foxp3
-
 T cells acetone 
 
Urine NMR 
 
Lean Obese 
BAL cells Total BALF cell number N-acetyl glycoprotein glucose 
 
CD3
+
CD4
+
 T cells N-methylnicotinamide 
3-hydroxybutyrate, 
glucose, N-acetyl 
glycoprotein, taurine 
 
CD4
+
CD25
+
 T cells 
N-methylnicotinamide, 
trimethylamine 
2-oxovalerate, ascorbate, 
creatine, creatinine, 
glucose 
 
CD4
+
CD25
+
FoxP3
-
 T cells 
guanidinoacetate, N-
methylnicotinamide, trimethylamine 
2-oxovalerate, ascorbate, 
creatine, creatinine 
 
CD4
+
CD25
+
Foxp3
+
 T cells 
 
2-oxovalerate, ascorbate, 
creatinine 
 
CD4
+
FoxP3
+
 T cells 
 
glucose 
 
CD4
+
FoxP3
hi
 T cells 
 
2-oxovalerate 
  
1
1
3
 
 
CD3
+
CD8
+
 T cells 3-hydroxybutyrate glucose 
 
CD8
+
CD25
+
 T cells 3-hydroxybutyrate 
 
 
CD8
+
DbNP366-74
+ T cells 
creatine, creatinine, indoxylsulfate, 
N-acetyl glycoprotein, 
phenoacetylglycine, taurine 
glucose 
 
CD8
+
CD25
+
DbNP366-74
+  T cells 
ascorbate, creatine, creatinine, 
indoxylsulfate, N-acetyl 
glycoprotein, phenoacetylglycine, 
taurine 
glucose, guanidinoacetate, 
indoxylsulfate, p cresol 
glucuronide, 
phenoacetylglycine 
mLN cells mLN cell number 
 
2-oxovalerate, creatinine 
 
CD3
+
CD4
+
 T cells 
N-methylnicotinamide, 
trimethylamine 
2-oxovalerate, creatinine, 
glucose 
 
CD4
+
CD25
+
 T cells 
 
2-oxovalerate, ascorbate, 
creatinine, dimethylamine, 
glucose, N-
methylnicotinamide 
 
CD4
+
CD25
+
Foxp3
-
 T cells indoxylsulfate 
2-oxovalerate, ascorbate, 
creatinine 
 
CD4
+
CD25
+
Foxp3
+ 
T cells 
 
2-oxovalerate ascorbate, 
creatinine, dimethylamine, 
glucose, N-
methylnicotinamide 
  
1
1
4
 
 
 
 
Table 5.5: Underlined text represents a significant negative correlation, and text without an underline indicates a significant positive 
association. All 
1
H NMR data are from tissues harvested at 9 dpi or urine and feces harvested at 6 dpi. Correlation analysis is based on 
a Pearson correlation matrix validated by 10,000 permutations. n=8-9. 
 
 
 
 
CD4
+
Foxp3
+
 T cells 
 
2-oxovalerate, ascorbate, 
creatinine, dimethylamine, 
glucose, N-
methylnicotinamide 
 
CD4
+
Foxp3
hi
 T cells indoxylsulfate 
Ascorbate, creatinine, 
dimethylamine, glucose, 
N-methylnicotinamide 
 
CD3
+
CD8
+
 T cells 
N-methylnicotinamide, 
trimethylamine 
2-oxovalerate, creatinine, 
glucose, 
phenoacetylglycine 
 
CD8
+
DbNP366-74
+ T cells 3-hydroxybutyrate 
guanidinoacetate, 
indoxylsulfate, p cresol 
glucuronide, 
phenoacetylglycine 
 
CD8
+
CD25
+
DbNP366-74
+  T cells 
 
guanidinoacetate, 
indoxylsulfate, p cresol 
glucuronide, 
phenoacetylglycine 
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Figure 5.1 Summary of influenza infection and metabolic profiling model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. A, Weanling, male C57BL6/J mice were maintained on a high fat (45% kcal fat) or 
low fat control diet (10% kcal fat) for 20 wks, n≥9. B) Timeline of samples harvested for 
metabolic profiling. Lean and obese mice were infected with 1.1x10
2
 TCID50 of influenza 
A/PR/8/34, and urine and feces were collected at -1 (uninfected mice), 2 and 6 dpi. Terminal 
samples (mLN, BALF, serum, liver, WAT and lungs) were collected from the same cohort of 
mice at 9 dpi. Flow cytometry was used to enumerate BAL and mLN T cell populations for 
immune-metabolic integration, n=8-9. C) Absolute weight loss in lean and obese mice following 
PR/8 infection, n≥9. D) Percent weight loss normalized to pre-infection body weight, n≥9. 
Values represent mean   SEM, ***p<0.0005 compared with lean mice. 
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Figure 5.2 Metabolic profiling can distinguish urine samples from both uninfected and 
infected lean and obese mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Pre-processed 
1
H NMR urine spectra were analyzed using PCA and PLS-DA. Urine 
spectra from lean and obese mice were collected one day prior to infection and at 2 and 6 dpi. 
A&B The urine spectra from lean mice (A) and obese mice (B) showed clear separation 
according to time, in a PCA analysis. C, PLS-DA analysis showed additional separation between 
lean and obese mice for two selected time points (i.e. -1 dpi and 6 dpi). n=8-9. 
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Figure 5.3 Representative analysis of serum samples from infected lean and obese mice 
 
 
Figure 5.3. O-PLS-DA analysis comparing serum 
1
H NMR spectra of lean and obese mice at 9 
dpi. n=8-9. 
 
  
1
1
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Figure 5.4 Correlation analysis of lung analytes and lung and mLN T cell populations 
 
Figure 5.4. A&B, Correlation analysis of lung 
1
H NMR data and T cell populations in BALF (A) and mLN (B) reveals differential 
correlation patterns between lean and obese mice. n=8-9. 
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CHAPTER VI: SYNTHESIS 
 
Overview of research findings 
This doctoral dissertation demonstrates that obesity results in greater lung damage during 
primary and secondary pH1N1 infections in mice. The first aim of this proposal was to 
investigate the impact of obesity on the cross-reactive immune response to a secondary pH1N1 
influenza virus infection. In this model, obese mice unexpectedly had lower levels of cross-
reactive non-neutralizing NP antibodies following a primary PR8 infection, which likely 
contributed to greater viral burden in the lungs of obese mice. Additionally, obese mice had 
greater lung damage, lung inflammation and heightened cross-reactive CD8
+
 T cell responses 
during the secondary pH1N1 influenza infection. To address the discrepancy in lung damage and 
inflammation during this secondary challenge, we also investigated the impact of obesity on Treg 
distribution and function. Although Treg number was elevated in the lung airways of obese mice 
during the secondary challenge, Tregs isolated from obese mice were 40% less suppressive than 
Tregs isolated from lean mice. Taken together, excess viral titers and impaired Treg function 
likely contributed to greater lung damage during a secondary pH1N1 infection in obese mice 
(Figure 6.1). This data may help to explain why obese humans were at greater risk for severe 
pH1N1 infections. Perhaps infected obese individuals weren’t able to properly control antiviral 
immune responses, ultimately resulting in excessive inflammatory responses and collateral lung 
damage. 
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To further address the consequences of obesity on lung damage during pH1N1 infection, 
we utilized a primary pH1N1 infection model in diet- and genetically-induced obese mice (Table 
6.1 summarizes the diets used in this dissertation). Both models of obesity exhibited significantly 
greater mortality following pH1N1 infection compared with lean control mice. Unexpectedly, 
obese mice did not display any differences in lung viral titers, lung inflammation or lung 
pathology scores. However, obese mice exhibited significantly higher damage to the lung 
epithelium. Because we demonstrated Tregs isolated from obese mice had impaired function in 
Aim 1, we then measured Treg distribution during this primary infection. Diet- and genetic-
induced obese mice had fewer total Tregs and fewer activated Tregs in the lung airways.  
Leptin is a critical regulator of immune responses; however, obesity is characterized by 
hyperleptinemia. During the context of a pH1N1 infection, we demonstrated that obese mice 
have greater leptin levels in circulation and in the lung airways. While a deficiency of leptin is 
associated with an immunodeficient state, the consequences of excess leptin signaling remain 
unclear (2). We hypothesized that disruption of leptin signaling in T cells would ameliorate 
pH1N1 severity in obese mice. Therefore, we generated mice with conditional disruption of 
leptin signaling in T cells. Obese LepR
T-/-
 gained a similar level of weight compared with obese 
LepR
Tfl/fl
 mice. However, disruption of leptin signaling did not limit pH1N1 infection severity in 
obese mice. Therefore, leptin signaling in T cells is likely not a mediator of infection severity in 
obese mice. 
Although we addressed a possible mechanism of leptin signaling in T cells mediating 
pH1N1 severity in obese mice, focusing on one specific signaling pathway in one cell type is 
likely not the most informative approach given the complexity of other potential mechanisms 
contributing to differential infection outcomes. Therefore, we extended our analysis of the 
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consequences of obesity to include a metabolomics approach. 
1
H NMR based metabolic profiling 
revealed that obesity caused distinct perturbations in a number of metabolic pathways and 
metabolites in the lung and in peripheral biofluids. Not only did we identify unique biomarkers 
altered by obesity that could be used to generate hypotheses for the consequences of obesity on 
infection, but we also demonstrated that metabolic profiling of urine could be used to predict 
infection status or infection severity. Therefore, we established metabolic profiling as a useful 
methodology for uncovering explanatory mechanisms for greater influenza pathogenesis in obese 
mice and as useful tool for predicting influenza infection status and severity. 
 
How does obesity alter pH1N1 immunity? 
Understanding the impact of obesity on immunity is difficult for a variety of reasons. 
Like most diseases in which the immune system plays a role in pathogenesis (autoimmune, 
cancer, CVD etc.), a complex array of factors could contribute to alterations in immune cell 
function. Mouse models are useful for addressing this problem and dissecting possible 
mechanisms, whereby the effects of a certain enzyme, hormone, signaling pathway etc. can be 
genetically or pharmaceutically manipulated. However, the pathogenesis and consequences of 
obesity are complex. Molecular manipulation of enzymes or hormones in attempt to understand 
how obesity is associated with greater susceptibility of a certain disease state may affect weight 
gain and other characteristics or features of obesity, thereby confounding results. Ideally, 
manipulation of a suspected mechanism would not affect any of the characteristics of obesity 
(hyperleptinemia, chronic inflammation, insulin resistance etc.), and this would allow one to 
address the isolated effects of a proposed mechanism (without the secondary consequences of 
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affecting obesity). However, the immune system greatly influences obesity and the associated 
consequences (1).  
Although, an abundance of research has begun to focus on the consequences of obesity 
on immunity, the complexity of this research continues to grow. It is clear that obesity affects the 
function of immune cells in different ways; obesity does not cause a global impairment in all 
immune cells, but rather, it appears that obesity may differentially affect the function of each 
type of immune cell (and each subtype) (2). For example, leptin impairs Treg proliferation but 
enhances effector T cell proliferation (198). Further, obesity may only impact certain functions 
of immune cells, making it even more difficult to determine what experimental readouts to use.  
 
Does hyperleptinemia underlie the consequences of obesity on pH1N1 immunity?   
The molecular mechanisms for a number of findings from this dissertation remain 
unknown. For example, in obese mice we detected heightened CD8
+
 T cell responses during a 
secondary infection, impaired Treg function, impaired antibody responses and greater lung 
damage. As mentioned, a number of factors may interact to cause these outcomes. Leptin is a 
critical modulator of immunity, and obese mice exhibit chronic hyperleptinemia. It is possible 
that elevated leptin levels are responsible for all of the differential outcomes we observed. Leptin 
enhances CD8
+
 T cell proliferation, regulates Treg and B cell function, and could alter the 
function of a variety of cells involved in propagating greater lung damage in influenza infected 
obese mice. Hyperleptinemia could alter immune cell function through excess leptin signaling or 
may induce a state of leptin resistance. We favor a mechanism by which excess leptin signaling 
is responsible for the altered immune responses observed. 
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Central leptin resistance is a fairly well accepted phenomenon of obesity, whereby neurons 
become resistant to the effects of leptin signaling (2,263). Further, central leptin resistance has 
been shown to be caused by hyperleptinemia (264). Excess leptin signaling upregulates Jak/Stat 
signaling pathways resulting in up regulation of a number of STAT3 responsive genes, such as 
SOCS3 (2,263). SOCS3 impairs JAK2 and LepR phosphorylation, critical steps of leptin 
signaling (2,263). Whether obesity induces a state of leptin resistance in immune cells is less 
clear. Some arguments against a role for leptin resistance in immune cells contributing to greater 
pH1N1 severity are:  
1. Leptin is an acute phase inflammatory cytokine (2). It has been hypothesized that 
prolonged leptin signaling induces a state of resistance in immune cells. However, 
negative feedback mechanisms are in place for every inflammatory cytokine. Obesity 
also induces a state of low-grade, chronic inflammation. Yet, there are currently no 
proposed mechanisms whereby immune cells become resistant to TNFα or IL-6 signaling 
in an obese state. Further, during the context of an influenza infection, expression of 
some inflammatory cytokines are increased 100-1000 fold (significantly greater than fold 
increase in leptin levels which is typically in the range of 2-10 times greater) (78,79).  
2. Leptin enhances T cell proliferation and activation (2). However, most mouse models 
demonstrate that obese mice exhibit greater T cell activation and inflammation during 
pH1N1 infection. Similarly, obese mice tend to exhibit excessive inflammatory responses 
during pH1N1 infection, which would not be expected if immune cells were leptin 
resistant (2,14). 
3. Two studies have demonstrated that immune cells from obese rodents exhibit resistance 
to leptin signaling (265,266). However, these studies would have been strengthened by 
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including assessments of signaling activation of other inflammatory molecules. Perhaps 
these studies weren’t demonstrating selective leptin resistance, but rather a general 
impaired responsiveness to an inflammatory signal. Additionally, these studies did not 
link impaired leptin signaling to any functional readout, such as reduced proliferation or 
inflammatory function.  
4. We demonstrated that lean mice lacking leptin signaling in T cells were not more 
susceptible to pH1N1 infection. Although this is an isolated effect in T cells and does not 
assess other immune cells, this demonstrates that complete disruption of leptin signaling 
in T cells (which in theory would mimic a state of leptin resistance) does not increase 
pH1N1 susceptibility.  
Therefore, we hypothesize that hyperleptinemia alters immune defenses through excess leptin 
signaling rather than inducing a state of leptin resistance. 
 
Mechanisms of greater lung damage during pH1N1 infection 
Enhanced infection mortality is not simply due to an inability to control infectious virus 
in obese mice, as a number of studies have demonstrated greater influenza mortality despite a 
lack of differences in viral titers (2). Further, several investigations have demonstrated that 
obesity impairs the function of a variety of immune cells, of both innate and adaptive arms of 
immunity (2). However, there have been no studies clearly demonstrating a direct role for how 
impaired function of a specific immune cell contributes to greater mortality. Further, because 
differences in viral titers aren’t typically reported during primary influenza infections, it is 
unlikely that impaired antiviral immune cell responses are responsible for the discrepancy in 
infection severity (unless perhaps it’s an inability to respond to homeostatic signals that function 
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to control immune responses). In asking why obese mice are more susceptible to influenza 
infection, the first question to address is what is the cause of death in pH1N1 infected obese 
mice? 
The most concrete findings, regarding greater pH1N1 mortality in obese mice, which 
have been uncovered thus far, are 1) obese mice exhibit impaired lung healing during pH1N1 
infection (67), and 2) treatment with leptin monoclonal antibody ameliorates infection severity in 
obese mice (82). However, these findings are only suggestive of possible mechanisms, as neither 
study demonstrated a direct link or mechanism between these findings and pH1N1 mortality. Our 
findings also demonstrate that obese mice exhibit greater lung damage during primary and 
secondary pH1N1 infection. Therefore, perhaps greater lung damage is responsible for greater 
pH1N1 mortality.  
To address differences in lung pathology and damage during a primary pH1N1 infection 
between lean and obese mice, we scored H&E stained lung pathology slides, measured immune 
cell infiltration, inflammatory cytokine responses, and assayed damage to the lung epithelium. 
Despite significant differences in damage to the lung epithelium, we did not detect differences in 
lung pathology scores (which is a measurement of immune cell infiltration into bronchioles and 
alveoli), total BAL cell number, total lung number, nor did we detect striking differences in 
inflammatory cytokine responses in obese mice. This would suggest that lung damage is not 
mediated by inflammatory immune cells, but is likely due to impaired healing responses of 
epithelial cells. With that said, immune cells, such as M2 macrophages and Tregs, can mediate 
wound healing. Perhaps M2 macrophage healing is impaired in obese mice (studies to address 
this mechanism are currently in progress). However, there is very little known of the negative 
effects of obesity on alveolar/bronchial epithelial cell function. Future investigations should 
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address the impact of obesity on the function, healing capacity, and antiviral responses of lung 
epithelial cells to influenza infection. 
Although, it is likely that greater lung damage is responsible for the greater mortality of 
influenza infected obese mice, there are no studies demonstrating a direct role for excess lung 
damage in mediating mortality. Theoretically, impaired wound healing would impair gas 
exchange at alveolar-endothelial spaces, thus impairing breathing, lowering circulating levels of 
oxygen and ultimately leading to suffocation. However, there have been no studies to directly 
investigate whether obesity impairs gas exchange during influenza infection or if dying mice are 
suffocating. However, several studies have demonstrated that obese mice exhibit heightened 
airway hyperresponsiveness (AHR) (267,268). Although, there are differences in influenza 
infection models and AHR models, understanding the impact of obesity on lung physiology and 
lung inflammation is critical area of research that must be further investigated.  
As mentioned, a direct link between greater lung damage and pH1N1 mortality has not 
been established. Therefore, perhaps systemic consequences are at play or synergism between 
lung damage and other obesity-associated pathologies. This is where metabolomics or other 
systems biology approaches may be useful for generating hypotheses. For example, we identified 
greater levels of vitamin C in the urine of influenza infected obese mice (compared with 
uninfected obese mice and infected lean mice). Vitamin C is endogenously produced in mice and 
can be upregulated during pro-oxidant conditions (253, 256). Additionally we also uncovered 
perturbations in lipid metabolism in a variety of tissues and biofluids of obese mice. Therefore, 
perhaps greater levels of oxidative stress and altered lipid metabolism work together to enhance 
influenza severity in obese mice.   
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Recommendations for future research 
There are two key outcomes from this dissertation that should be addressed in future 
experiments: 
1) Greater damage to the lung epithelium of obese mice during a primary pH1N1 infection 
2) Impaired antibody responses following a primary, sublethal PR8 infection 
In addressing mechanisms for greater damage to the lung epithelium, this also has implications 
for understanding why obese mice are also more susceptible to death from pH1N1 infection. As 
discussed, it is possible that impairments in epithelial cell responses to pH1N1 infection underlie 
greater mortality in obese mice. Further, there are multiple mouse and human lung epithelial cell 
lines that would facilitate identification of a molecular mechanism. One important question to 
address is the impact of leptin on epithelial cell function in obese mice. An interesting model 
would be to cross LepR floxed mice with Surfactant protein C (SPC)-Cre mice, resulting in 
disruption of leptin signaling in Type II respiratory epithelial cells. This would help to determine 
if leptin signaling in epithelial cells drives greater pH1N1 severity. 
One striking finding from Aim I, is we demonstrated that obese mice exhibited impaired 
maintenance of influenza antibodies following a sublethal PR8 infection (14). This is interesting 
because we have also demonstrated that obese humans exhibit impaired maintenance of 
influenza antibodies following TIV vaccination (12). One critical aspect of obesity that should be 
further address is how the bone marrow microenvironment impacts the trafficking and 
maintenance of long lived plasma cells to the bone marrow. It has previously been shown that 
obesity causes dramatic changes to the bone marrow microenvironment including deposition of 
adipocytes and increased expression of leptin. Therefore, it would also be interesting to 
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determine if excess leptin signaling alters plasma cell trafficking, maintenance or function. By 
crossing LepR floxed mice with CD19-Cre mice, this could be achieved. 
Therefore, future investigations should focus on the role of leptin signaling, and the use 
of conditional knockout mice will facilitate this. Additionally, we have demonstrated that 
metabolic profiling can provide a more global perspective of the consequences of obesity on 
pH1N1 immunity. Therefore, this methodology could be integrated into future immunological 
assays to determine how complex changes in metabolism interact with alterations in the immune 
system. 
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Tables and Figures 
 
Table 6.1 Comparison of diets used in this dissertation 
Diet 
Fat 
Kcal% 
Carbohydrate 
Kcal % 
Protein 
Kcal % 
Primary 
Carbohydrate 
Source 
Primary 
Fat 
Source 
Fiber Phytoestrogens? 
Purified 
Ingredients? 
Micro- 
nutrient 
Content 
Matched 
Research 
Diets 
D12450B 
10 70 20 
Sucrose (35% 
Kcal) 
Soybean 
Oil (6% 
Kcal) 
Low 
(cellulose) 
No Yes Yes 
Research 
Diets 
D12451 
45 35 20 
Sucrose (17% 
Kcal) 
Lard (39% 
Kcal) 
Low 
(cellulose) 
No 
Yes 
 
Yes 
Research 
Diets 
D12492 
60 20 20 
Maltodextrin 10 
(12% Kcal) 
Lard (54% 
Kcal) 
Low 
(cellulose) 
No Yes Yes 
ProLab 
3000 Chow 
14.3 59.7 26 Starch (32.6%) 
Acid 
hydrolysis 
Hi (various 
sources) 
Yes No No 
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Figure 6.1 Summary of heterologous infection data 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Obesity mice had fewer cross-reactive, non-neutralizing nucleoprotein antibodies 
during a secondary pH1N1 challenge. This likely contributed to greater levels of infectious virus, 
which subsequently triggered overactive immune responses and excess lung damage. Further, 
obese mice exhibited impaired Treg function, which likely further propagated this excess lung 
damage in obese mice.  
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